Making Money Trading Stem Cell Company Stocks

Stem Cell Company Stocks 11/01/09

2009-11-01T20:51:00.003-05:00

October ended frantically as the market sold off due mostly to mutual funds locking in end of fiscal year profits. Practically every sector dropped significantly and the stem cell stocks were no exception.

Top Stem Cell Stock Performer(s) the Last Two Weeks:

- BioTime, Inc. (BTIM) = Up 26%; This pop on news that it was moving to AMEX. These stocks typically tank once they officially move. Could be a shorting opportunity

Worst Stem Cell Stock Performer(s) the Last Two Weeks:

- StemCell Inc. (STEM) = Down -29%; This stock tanked due to equity financing (A.K.A dilution). The exercise price is much higher than the current share price and the dilution is less than 10%. This looks to be a bit overdone and could be a bounce candidate.

Stem Cell Stocks Current Price and % Up or Down 10/19/09 - 10/30/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $1.80; Down -18%
Aastrom Biosciences (ASTM) = Cur Price: $0.32; Down -11%
BioTime, Inc. (BTIM) = Cur Price: $5.87; Up 26%
Celgene Corp (CELG) = Cur Price: $51.05; Down -10%
Cytori Therapeutics (CYTX) = Cur Price: $3.29; Down -11%
Geron Corp (GERN) = Cur Price: $6.11; Down -6%
ThermoGenesis (KOOL) = Cur Price: $0.59; Down -14%
Osiris Therapeutics (OSIR) = Cur Price: $6.35; Down -10%
StemCell Inc. (STEM) = Cur Price: $1.14; Down -29%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.113; Down -5%
Athersys Inc. (ATHX) = Cur Price: $1.17; Up 1%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.31; Up 12%
Bioheart Inc. (BHRT.OB) = Cur Price: $0.91; Down -12%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.006; Unchanged
Cyro-Cell Intl (CCEL.OB) = Cur Price: $1.75; Down -18%
Neuralstem (CUR) = Cur Price: $1.27; Down -18%
International Stem Cell (ISCO.OB) = Cur Price: $0.64; Down -11%
MultiCell Technologies (MCET.OB) = Cur Price: $0.018; Down -14%
Pluristem Therapeutics (PSTI) = Cur Price: $0.98; Down -14%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.159; Down -9%
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.0021; Down -16%

Catalyst(s):

Still, nothing has changed from the last few months.

- M&A (mergers and acquisitions) activity will be key.

Stem Cell Company Stocks 10/18/09

2009-10-09T20:55:00.003-04:00

The DOW broke a 10000 last week and has been rolling along much of 2009. Most of the large cap stem cell stocks have followed the market the past two weeks, but the others have moved sporadically. The sector is still looking for a catalyst.

Top Stem Cell Stock Performer(s) the Last Two Weeks:

- ThermoGenesis (KOOL) = Up 11%; KOOL's been trading in a tight range for 8 or 9 months. It has broke out yet, but it's worth keeping an eye on it.

Worst Stem Cell Stock Performer(s) the Last Two Weeks:

- Bioheart Inc. (BHRT.OB) = Down -38%; This stock spiked at the beginning of September and has fallen ever since. Based on the chart, the fall isn't done.

Stem Cell Stocks Current Price and % Up or Down 10/05/09 - 10/16/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $2.20; Up 8%
Aastrom Biosciences (ASTM) = Cur Price: $0.36; Down -13%
BioTime, Inc. (BTIM) = Cur Price: $4.66; Down -14%
Celgene Corp (CELG) = Cur Price: $56.42; Up 4%
Cytori Therapeutics (CYTX) = Cur Price: $3.69; Up 1%
Geron Corp (GERN) = Cur Price: $6.50; Up 3%
ThermoGenesis (KOOL) = Cur Price: $0.689; Up 11%
Osiris Therapeutics (OSIR) = Cur Price: $7.03; Up 8%
StemCell Inc. (STEM) = Cur Price: $1.60; Up 3%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.119; Up 5%
Athersys Inc. (ATHX) = Cur Price: $1.16; Up 2%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.278; Down -13%
Bioheart Inc. (BHRT.OB) = Cur Price: $1.15; Down -38%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.006; Down -23%
Cyro-Cell Intl (CCEL.OB) = Cur Price: $2.14; Down -3%
Neuralstem (CUR) = Cur Price: $1.54; Up 6%
International Stem Cell (ISCO.OB) = Cur Price: $0.72; Up 3%
MultiCell Technologies (MCET.OB) = Cur Price: $0.021; Down -9%
Pluristem Therapeutics (PSTI) = Cur Price: $1.14; Down -15%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.175; Down -27%
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.0025; Down -24%

Catalyst(s):

Still, nothing has changed from the last few months.

- M&A (mergers and acquisitions) activity will be key.

Stem Cell Company Stocks 10/4/09

2009-10-04T20:44:00.004-04:00

The overall market is going through a bit of a correction after an unsustainable series of up days. The stem cell stocks have been hit just like the rest of the market. There still has been no real spark in the sector.

Top Stem Cell Stock Performer(s) the Last Two Weeks:

- Cord Blood America Inc. (CBAI.OB) = Up 152%; This move was caused by a combination of technicals and a series of news releases. This happens periodical with this stock. It looks like the fade has already begun.

Worst Stem Cell Stock Performer(s) the Last Two Weeks:

- Neurostem Inc. (CUR) = Down -22%; This stock is just retracing from a quick double a couple of weeks back. The fall happens to be just as fast the rise. Stay away.

Stem Cell Stocks Current Price and % Up or Down 9/21/09 - 10/2/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $2.03; Down -19%
Aastrom Biosciences (ASTM) = Cur Price: $0.414; Down -2%
BioTime, Inc. (BTIM) = Cur Price: $5.45; Up 21%
Celgene Corp (CELG) = Cur Price: $54.00; Up 3%
Cytori Therapeutics (CYTX) = Cur Price: $3.66; Up 3%
Geron Corp (GERN) = Cur Price: $6.31; Down -15%
ThermoGenesis (KOOL) = Cur Price: $0.62; Down -4%
Osiris Therapeutics (OSIR) = Cur Price: $6.53; Down -18%
StemCell Inc. (STEM) = Cur Price: $1.55; Down -11%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.113; Down -12%
Athersys Inc. (ATHX) = Cur Price: $1.14; Up 9%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.32; Up 16%
Bioheart Inc. (BHRT) = Cur Price: $1.85; Down -12%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.0078; Up 152%
Cyro-Cell Intl (CCEL.OB) = Cur Price: $2.20; Up 5%
Neuralstem (CUR) = Cur Price: $1.45; Down -22%
International Stem Cell (ISCO.OB) = Cur Price: $0.70; Down -19%
MultiCell Technologies (MCET.OB) = Cur Price: $0.023; Up 5%
Pluristem Therapeutics (PSTI) = Cur Price: $1.34; Up 3%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.24; Down -4%
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.0033; Up 18%

Catalyst(s):

Still, nothing has changed from the last few months.

- M&A (mergers and acquisitions) activity will be key.

Stem Cell Company Stocks 9/20/09

2009-09-20T14:52:00.004-04:00

For the most part, the stem cell stocks are still individually driven by news. However, many of the larger cap names seem to be moving higher along with the overall market. We'll see if that continues to hold true as the market inches closer to DOW 10000.

Top Stem Cell Stock Performer(s) the Last Two Weeks:

- Stem Cell Therapy Intl (SCII.OB) = Up 614%; This stock spiked when the company agreed to be a party to a settlement where Histostem and Stem Cell Therapy Intl merge. This was a monstrous gain for such a small and obscure stock. It's already pulled back a lot from a high of $0.50/share, but I would still be hesitant to chase.

Worst Stem Cell Stock Performer(s) the Last Two Weeks:

- Osiris Therapeutics (OSIR) = Down -35%; This stock's stem cell drug failed two late stage studies and the CFO quit. Talk about a stock killer. I'd wait for this one to cool off some before I'd even consider buying.

Stem Cell Stocks Current Price and % Up or Down 9/07/09 - 9/18/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $2.51; Up 7%
Aastrom Biosciences (ASTM) = Cur Price: $0.424; Down -1%
BioTime, Inc. (BTIM) = Cur Price: $4.50; Up 29%
Celgene Corp (CELG) = Cur Price: $52.54; Up 2%
Cytori Therapeutics (CYTX) = Cur Price: $3.55; Up 14%
Geron Corp (GERN) = Cur Price: $7.41; Up 3%
ThermoGenesis (KOOL) = Cur Price: $0.644; Up 4%
Osiris Therapeutics (OSIR) = Cur Price: $7.97; Down -35%
StemCell Inc. (STEM) = Cur Price: $1.74; Up 2%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.129; Down -17%
Athersys Inc. (ATHX) = Cur Price: $1.05; Up 7%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.275; Up 15%
Bioheart Inc. (BHRT) = Cur Price: $2.10; Up 173%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.0031; Up 3%
Cyro-Cell Intl (CCEL.OB) = Cur Price: $2.10; Down -7%
Neuralstem (CUR) = Cur Price: $1.87; Up 64%
International Stem Cell (ISCO.OB) = Cur Price: $0.86; Up 5%
MultiCell Technologies (MCET.OB) = Cur Price: $0.022; Down -6%
Pluristem Therapeutics (PSTI) = Cur Price: $1.30; Down -1%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.25; Up 614%
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.0028; Down -7%

Catalyst(s):

Still, nothing has changed from the last few months.

- M&A (mergers and acquisitions) activity will be key.

Stem Cell Company Stocks 9/6/09

2009-09-07T16:39:00.005-04:00

The mixed bag for stem cell stocks continues. Pops seem to only occur with news on individual stocks.

Top Stem Cell Stock Performer(s) the Last Two Weeks:

- Brainstorm Cell Therapeutics (BCLI) = Up 293%; A stem cell production deal cause the stock to spike. The shares hit a 52 week high of $0.38, but has dropped quickly. I'd monitor this stock after a 50% retracement to see if this is just a flash in the pan.

Worst Stem Cell Stock Performer(s) the Last Two Weeks:

- MultiCell Technologies (MCET.OB) = Down -22%; This wasn't quite the biggest loser, but was the most predictable. As suggested during thr previous post, the gains didn't hold from the patent news.

Stem Cell Stocks Current Price and % Up or Down 8/24/09 - 9/4/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $2.35; Up 11%
Aastrom Biosciences (ASTM) = Cur Price: $0.43; Down -4%
BioTime, Inc. (BTIM) = Cur Price: $3.50; Up 13%
Celgene Corp (CELG) = Cur Price: $51.74; Down -3%
Cytori Therapeutics (CYTX) = Cur Price: $3.12; Down -3%
Geron Corp (GERN) = Cur Price: $7.21; Up 11%
ThermoGenesis (KOOL) = Cur Price: $0.62; Down -10%
Osiris Therapeutics (OSIR) = Cur Price: $12.21; Unchanged
StemCell Inc. (STEM) = Cur Price: $1.70; Up 4%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.155; Up 31%
Athersys Inc. (ATHX) = Cur Price: $0.98; Up 1%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.24; Up 293%
Bioheart Inc. (BHRT) = Cur Price: $0.77; Up 28%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.003; Down -3%
Cyro-Cell Intl (CCEL.OB) = Cur Price: $2.25; Up 13%
Neuralstem (CUR) = Cur Price: $1.14; Up 5%
International Stem Cell (ISCO.OB) = Cur Price: $0.82; Unchanged
MultiCell Technologies (MCET.OB) = Cur Price: $0.0235; Down -22%
Pluristem Therapeutics (PSTI) = Cur Price: $1.31; Down -10%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.035; Down -27%
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.003; Down -6%

Catalyst(s):

Still, nothing has changed from the last few months.

- M&A (mergers and acquisitions) activity will be key.

Stem Cell Company Stocks 8/23/09

2009-08-22T22:14:00.004-04:00

The Dow is currently at 9500 and everything is moving higher except the stem cell stocks. Even star performers like GERN are CYTX have turned south. This sector is in major need of a catalyst.

Top Stem Cell Stock Performer(s) the Last Two Weeks:

- MultiCell Technologies (MCET.OB) = Up 233%; This one spiked on a patent approval. Most traders know this stock has a very tight float and typically makes big moves when it does move. The gains never hold, so don't jump in late.

Worst Stem Cell Stock Performer(s) the Last Two Weeks:

- Bioheart Inc. (BHRT.OB) = Down -27%; The stock dropped for no particular reason and it's currently sitting around its 52 week low. This is potentially a good bounce play, but be careful with the low volume.

Stem Cell Stocks Current Price and % Up or Down 8/10/09 - 8/21/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $2.12; Up 12%
Aastrom Biosciences (ASTM) = Cur Price: $0.45; Up 2%
BioTime, Inc. (BTIM) = Cur Price: $3.10; Down -12%
Celgene Corp (CELG) = Cur Price: $53.15; Down -3%
Cytori Therapeutics (CYTX) = Cur Price: $3.20; Unchanged
Geron Corp (GERN) = Cur Price: $6.52; Down -15%
ThermoGenesis (KOOL) = Cur Price: $0.69; Unchanged
Osiris Therapeutics (OSIR) = Cur Price: $12.25; Up 7%
StemCell Inc. (STEM) = Cur Price: $1.63; Down -1%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.118; Down -19%
Athersys Inc. (ATHX) = Cur Price: $0.97; Down -5%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.061; Down -13%
Bioheart Inc. (BHRT) = Cur Price: $0.60; Down -27%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.0031; Down -3%
Cyro-Cell Intl (CCEL.OB) = Cur Price: $2.00; Up 18%
Neuralstem (CUR) = Cur Price: $1.09; Down -11%
International Stem Cell (ISCO.OB) = Cur Price: $0.82; Down -7%
MultiCell Technologies (MCET.OB) = Cur Price: $0.03; Up 233%
Pluristem Therapeutics (PSTI) = Cur Price: $1.45; Up 4%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.048; Up 7%
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.0032; Up 14%

Catalyst(s):

Still, nothing has changed from the last few months.

- M&A (mergers and acquisitions) activity will be key.

Stem Cell Company Stocks 8/08/09

2009-08-08T20:07:00.004-04:00

The stock market isn't letting up but the stem cell stock trade is practically dead. GERN and CYTX have been solid performers as large caps during the overall market's run. However, the small caps have done basically nothing as a whole. We'll continue to monitor them all.

Top Stem Cell Stock Performer(s) the Last Two Weeks:

- Brainstorm Cell Therapeutics (BCLI.OB) = Up 37%; This was one of the worst performers two weeks ago. This is typical penny stock action. I wouldn't read too much into this one.

Worst Stem Cell Stock Performer(s) the Last Two Weeks:

-Osiris Therapeutics (OSIR) = Down -10%; This stock is hovering around its 52 week low. Keep an eye out for this one. It may be due for a bounce.

Stem Cell Stocks Current Price and % Up or Down 7/27/09 - 8/7/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $1.89; Up 9%
Aastrom Biosciences (ASTM) = Cur Price: $0.44; Up 13%
BioTime, Inc. (BTIM) = Cur Price: $3.53; Up 9%
Celgene Corp (CELG) = Cur Price: $55.05; Up 1%
Cytori Therapeutics (CYTX) = Cur Price: $3.21; Down -5%
Geron Corp (GERN) = Cur Price: $7.63; Down -5%
ThermoGenesis (KOOL) = Cur Price: $0.69; Up 3%
Osiris Therapeutics (OSIR) = Cur Price: $11.44; Down -10%
StemCell Inc. (STEM) = Cur Price: $1.64; Down -2%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.145; Down -11%
Athersys Inc. (ATHX) = Cur Price: $1.02; Up 15%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.07; Up 37%
Bioheart Inc. (BHRT) = Cur Price: $0.82; Up 11%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.0032; Down -6%
Cyro-Cell Intl (CCEL.OB) = Cur Price: $1.70; Down -4%
Neuralstem (CUR) = Cur Price: $1.22; Up 14%
International Stem Cell (ISCO.OB) = Cur Price: $0.88; Down -3%
MultiCell Technologies (MCET.OB) = Cur Price: $0.009; Up 18%
Pluristem Therapeutics (PSTI) = Cur Price: $1.39; Down -3%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.045; Down -10%
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.0028; Down -7%

Catalyst(s):

Still, nothing has changed from the last few months.

- M&A (mergers and acquisitions) activity will be key.

Stem Cell Company Stocks 7/26/09

2009-07-12T13:17:00.005-04:00

As expected, the market has exploded higher thanks to improved earnings from a large percentage of reporting companies. Even the stem cell stocks are being pushed up. The larger cap stocks in the sector seem to be performing the strongest. It'll be interesting to see if this trend continues.

Top Stem Cell Stock Performer(s) the Last Two Weeks:

- Cryo-Cell International (CCEL.OB) = Up 25%; After a slight retracement from positive earnings report, this stock has resumed it's upward climb.

Worst Stem Cell Stock Performer(s) the Last Two Weeks:

-MultiCell Technologies Inc. (MCET.OB) = Down -31%; There has been no news from the company. The stock is acting like a typical penny stock. It's heading back down to it's 52 week low. I would even consider this one until it gets there.

Stem Cell Stocks Current Price and % Up or Down 7/13/09 - 7/24/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $1.73; Up 12%
Aastrom Biosciences (ASTM) = Cur Price: $0.388; Up 3%
BioTime, Inc. (BTIM) = Cur Price: $3.25; Down -1%

Celgene Corp (CELG) = Cur Price: $54.64; Up 19%
Cytori Therapeutics (CYTX) = Cur Price: $3.39; Up 7%
Geron Corp (GERN) = Cur Price: $7.99; Up 9%
ThermoGenesis (KOOL) = Cur Price: $0.67; Up 19%
Osiris Therapeutics (OSIR) = Cur Price: $12.76; Up 11%
StemCell Inc. (STEM) = Cur Price: $1.67; Up 6%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.163; Up 1%
Athersys Inc. (ATHX) = Cur Price: $0.89; Up 11%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.051; Down -27%
Bioheart Inc. (BHRT) = Cur Price: $0.74; Up 6%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.0034; Up 3%
Cyro-Cell Intl (CCEL.OB) = Cur Price: $1.77; Up 25%
Neuralstem (CUR) = Cur Price: $1.07; Down -6%
International Stem Cell (ISCO.OB) = Cur Price: $0.91; Up 5%
MultiCell Technologies (MCET.OB) = Cur Price: $0.0076; Down -31%
Pluristem Therapeutics (PSTI) = Cur Price: $1.43; Up 11%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.05; Unchanged
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.003; Unchanged

Catalyst(s):

Still, nothing has changed from the last few months.

- M&A (mergers and acquisitions) activity will be key.

Stem Cell Stocks 7/12/09: The Past Two Weeks

2009-07-12T13:17:00.004-04:00

The overall market is continuing its slide. Most people are waiting to see how it responds at key technical points of 850 on the S&P and 8000 on the DOW. Meanwhile, i've been interested to see how the stem cell stocks perform. It was one of the few sectors that performed well when market initially tanked at the end of 2008. However, overall there hasn't been a repeat performance.

Top Stem Cell Stock Performer(s) the Last Two Weeks:

- BioTime Inc. (BTIM.OB) = Up 37%; A stem cell marketing agreement was announce by Biotime with Millipore. The price rose on 5 times the average daily volume. This stock has a history of spiking then falling quickly. I wouldn't recommend chasing.

Worst Stem Cell Stock Performer(s) the Last Two Weeks:

-Advanced Cell Technology (ACTC.OB) = Down -36%; After a huge move 2 weeks ago, ACTC.OB was unable to break out of that 25-30 cents range. Once it failed, it made for a great short opportunity. It's hard to say when the freefall will end.

Stem Cell Stocks Current Price and % Up or Down 6/29/09 - 7/10/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $1.54; Down -7%
Aastrom Biosciences (ASTM) = Cur Price: $0.375; Down -6%
BioTime, Inc. (BTIM.OB) = Cur Price: $3.28; Up 37%
Celgene Corp (CELG) = Cur Price: $46.10; Down -4%
Cytori Therapeutics (CYTX) = Cur Price: $3.18; Down -19%
Geron Corp (GERN) = Cur Price: $7.32; Up 5%
ThermoGenesis (KOOL) = Cur Price: $0.565; Down-9%
Osiris Therapeutics (OSIR) = Cur Price: $11.53; Down -13%
StemCell Inc. (STEM) = Cur Price: $1.57; Down -13%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.162; Down -36%
Athersys Inc. (ATHX) = Cur Price: $0.80; Down -4%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.0695; Down -1%
Bioheart Inc. (BHRT) = Cur Price: $0.70; Down -18%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.0033; Down -13%
Cyro-Cell Intl (CCEL.OB) = Cur Price: $1.42; Up 23%
Neuralstem (CUR) = Cur Price: $1.14; Down -5%
International Stem Cell (ISCO.OB) = Cur Price: $0.87; Up 9%
MultiCell Technologies (MCET.OB) = Cur Price: $0.011; Up 5%
Pluristem Therapeutics (PSTI) = Cur Price: $1.29; Up 2%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.05; Unchanged
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.03; Down -17%

Catalyst(s):

Still, nothing has changed from the last few months.

- M&A (mergers and acquisitions) activity will be key. I can't believe that there hasn't been any activity yet, but I think it will happen as the economy improves.

Stem Cell Stocks 6/27/09: The Past Two Weeks

2009-06-28T15:44:00.006-04:00

Because of the stagnant nature in which the stem cell stocks have been performing the last few months, I've decide to adjust my posting intervals to every two weeks. Once again, select names have been performing steadily, but overall nothing special has occurred in the sector.

Top Stem Cell Stock Performer(s) the Last Two Weeks:

- Advanced Cell Technology (ACT.OB) = Up 51%; There's been no real news, but the stock's been on a technical tear. If it breaks out of the 25-30 cent range, it could double.

Worst Stem Cell Stock Performer(s) the Last Two Weeks:

-ThermoGenesis Corp. (KOOL) = Down -15%; After a 50% spike up a few weeks ago, this stock has come crashing back down to earth. It looks like it needs news to move higher.

Stem Cell Stocks Current Price and % Up or Down 6/15/09 - 6/26/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $1.66; Down -11%
Aastrom Biosciences (ASTM) = Cur Price: $0.40; Up 14%
BioTime, Inc. (BTIM) = Cur Price: $2.40; Down -9%
Celgene Corp (CELG) = Cur Price: $48.03; Up 11%
Cytori Therapeutics (CYTX) = Cur Price: $3.95; Down -2%
Geron Corp (GERN) = Cur Price: $6.95; Up 1%
ThermoGenesis (KOOL) = Cur Price: $0.62; Down-15%
Osiris Therapeutics (OSIR) = Cur Price: $13.25; Down -5%
StemCell Inc. (STEM) = Cur Price: $1.80; Up 8%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.252; Up 51%
Athersys Inc. (ATHX) = Cur Price: $0.83; Down -12%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.07; Down -6%
Bioheart Inc. (BHRT) = Cur Price: $0.85; Up 1%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.0038; Down -7%
Cyro-Cell Intl (CCEL.OB) = Cur Price: $1.15; Down -4%
Neuralstem (CUR) = Cur Price: $1.20; Up 10%
International Stem Cell (ISCO.OB) = Cur Price: $0.80; Down-13%
MultiCell Technologies (MCET.OB) = Cur Price: $0.0105; Down -19%
Pluristem Therapeutics (PSTI) = Cur Price: $1.27; Down -5%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.05; Down -9%
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.036; Down -5%

Catalyst(s):

Still, nothing has changed from the last few months.

- M&A (mergers and acquisitions) activity will be key. I can't believe that there hasn't been any activity yet, but I think it will happen as the economy improves.

Stem Cell Stocks 6/14/09: The Week That Was

2009-06-13T21:38:00.008-04:00

It appears that the moved in the stem cell stocks two weeks ago was nothing more the a blip on the radar. Last week was much of the same mixed bag action we've seen the past 3 or 4 months. I believe these stocks are still waiting for a catalyst to break through.

Top Stem Cell Stock Performer(s) for Last Week:

None

Worst Stem Cell Stock Performer(s) for Last Week:

-Stem Cell Innovations (SCLL.OB) = Down -21%; This stock has been getting killed since its brief run in February. There has been no news, just continued downward pressure.

Stem Cell Stocks Current Price and % Up or Down 6/8/09 - 6/12/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $1.86; Up 12%
Aastrom Biosciences (ASTM) = Cur Price: $0.351; Down -3%
BioTime, Inc. (BTIM) = Cur Price: $2.63; Down -6%
Celgene Corp (CELG) = Cur Price: $43.23; Down -3%
Cytori Therapeutics (CYTX) = Cur Price: $4.04; Down -8%
Geron Corp (GERN) = Cur Price: $6.85; Unchanged
ThermoGenesis (KOOL) = Cur Price: $0.73; Unchanged
Osiris Therapeutics (OSIR) = Cur Price: $13.91; Down -1%
StemCell Inc. (STEM) = Cur Price: $1.66; Down -5%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.167; Up 8%
Athersys Inc. (ATHX) = Cur Price: $0.94; Up 5%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.0748; Up 3%
Bioheart Inc. (BHRT) = Cur Price: $0.84; Up 6%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.0041; Up 3%
Cyro-Cell Intl (CCEL.OB) = Cur Price: $1.20; Down -4%
Neuralstem (CUR) = Cur Price: $1.09; Down -8%
International Stem Cell (ISCO.OB) = Cur Price: $0.92; Up 1%
MultiCell Technologies (MCET.OB) = Cur Price: $0.0129; Down -13%
Pluristem Therapeutics (PSTI) = Cur Price: $1.33; Up 5%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.055; Up 12%
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.038; Down -21%

Catalyst(s):

Nothing has changed from the last few months.

- M&A (mergers and acquisitions) activity will be key. I can't believe that there hasn't been any activity yet, but I think it will happen as the economy improves.

Stem Cell Stocks 6/07/09: The Week That Was

2009-06-06T22:19:00.006-04:00

Mark this week's post as the start of a possible stem cell stock turnaround. For the first time since January, every larger cap stem cell stock that we follow finished the week in positive territory. The sector has not done much in last three months with the exception of moves the last month by Geron and Cytori Therapeutics. There has been no notable catalyst that has caused this shift in activity. As a result, a follow up week will be big in determining if the stem cell stocks have new life.

Top Stem Cell Stock Performer(s) for Last Week:

- ThermoGenesis Corp (KOOL) = Up 38% for the week; Volume jumped significantly in KOOL during later part of the week. Either news is coming or institutions have begun to buy

Worst Stem Cell Stock Performer(s) for Last Week:

-Stem Cell Therapy Intl (SCII.OB) = Down -18; This stock has been in free fall from $0.12/share since April. Based on the chart, I wouldn't consider buying this until it hits $0.02 a share

Stem Cell Stocks Current Price and % Up or Down 6/1/09 - 6/5/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $1.66; Up 11%
Aastrom Biosciences (ASTM) = Cur Price: $0.361; Up 8%
BioTime, Inc. (BTIM) = Cur Price: $2.80; Up 10%
Celgene Corp (CELG) = Cur Price: $44.35; Up 5%
Cytori Therapeutics (CYTX) = Cur Price: $4.37; Up 15%
Geron Corp (GERN) = Cur Price: $6.83; Up 5%
ThermoGenesis (KOOL) = Cur Price: $0.73; Up 38%
Osiris Therapeutics (OSIR) = Cur Price: $14.11; Up 12%
StemCell Inc. (STEM) = Cur Price: $1.75; Up 7%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.155; Up 5%
Athersys Inc. (ATHX) = Cur Price: $0.899; Up 7%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.0725; Up 4%
Bioheart Inc. (BHRT) = Cur Price: $0.79; Down -6%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.004; Down -2%
Cyro-Cell Intl (CCEL.OB) = Cur Price: $1.25; Unchanged
Neuralstem (CUR) = Cur Price: $1.19; Up 13%
International Stem Cell (ISCO.OB) = Cur Price: $0.91; Down -9%
MultiCell Technologies (MCET.OB) = Cur Price: $0.0149; Down -10%
Pluristem Therapeutics (PSTI) = Cur Price: $1.27; Up 2%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.049; Down -18%
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.048; Unchanged

Catalyst(s):

Nothing has changed from the last few months.

- M&A (mergers and acquisitions) activity will be key. I can't believe that there hasn't been any activity yet, but I think it will happen as the economy improves

Stem Cell Stocks 5/31/09: The Week That Was

2009-05-30T23:40:00.005-04:00

Last week consisted of more sporadic trading for the stem cell stocks. I'm still trying to figure out if there is some correlation between the general market and the stem cell sector, but as of right now, nothing stands out.

Top Stem Cell Stock Performer(s) for Last Week:

- International Stem Cell Corp (ISCO.OB) = Up 47% for the week; Mid-week ISCO.OB received positive early results from animal trials designed to improve photorefractive keratectomy (PRK), a form of corrective laser eye surgery that offers an improved alternative to LASIK.

Worst Stem Cell Stock Performer(s) for Last Week:

Cord Blood America Inc. (CBAI.OB) = Down -15%; This stock was flat all week and then tanked the last hour of the last trading day of the week. It looks like frustrated traders are throwing in the towel.

Stem Cell Stocks Current Price and % Up or Down 5/25/09 - 5/29/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $1.50; Up 8%
Aastrom Biosciences (ASTM) = Cur Price: $0.335; Down -7%
BioTime, Inc. (BTIM) = Cur Price: $2.55; Down -3%
Celgene Corp (CELG) = Cur Price: $42.24; Up 7%
Cytori Therapeutics (CYTX) = Cur Price: $3.79; Up 32%
Geron Corp (GERN) = Cur Price: $6.52; Down -4%
ThermoGenesis (KOOL) = Cur Price: $0.53; Down -4%
Osiris Therapeutics (OSIR) = Cur Price: $12.61; Up 5%
StemCell Inc. (STEM) = Cur Price: $1.63; Down -3%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.148; Up 14%
Athersys Inc. (ATHX) = Cur Price: $0.84; Down -6%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.07; Down -8%
Bioheart Inc. (BHRT) = Cur Price: $0.84; Down -7%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.0041; Down -15%
Cyro-Cell Intl (CCEL.OB) = Cur Price: $1.25; Up 9%
Neuralstem (CUR) = Cur Price: $1.05; Down -5%
International Stem Cell (ISCO.OB) = Cur Price: $1.00; Up 47%
MultiCell Technologies (MCET.OB) = Cur Price: $0.0165; Up 38%
Pluristem Therapeutics (PSTI) = Cur Price: $1.24; Up 7%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.06; Down -8%
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.048; Down -4%

Catalyst(s):

Nothing has changed from the last few months.

- M&A (mergers and acquisitions) activity will be key. I can't believe that there hasn't been any activity yet, but I think it will happen as the economy improves.

Stem Cell Stocks 5/24/09: The Week That Was

2009-05-23T22:02:00.006-04:00

It was flat week for the most part for the stem cell stocks. Overall, the stocks that have fallen the hardest in the sector have finally begun to level out. As a result, now may finally be the time to consider buying select names in the sector. The only stem cell stock that has shown consistent upward movement over the last 3 months has been Geron Corp. (GERN).

Top Stem Cell Stock Performer(s) for Last Week:

- Bioheart Inc. (BHRT.OB) = Up 38%; The low volume continues to yield wild swings. If you recall, Bioheart was the worst performer of the group the previous week.

Worst Stem Cell Stock Performer(s) for Last Week:

- International Stem Cell Corp (ISCO.OB) = Down -22% for the week; With ISCO.OB being the best performer the previous week, we mentioned that it would be a good stock to short due to profit taking. It looks like we were right.

Stem Cell Stocks Current Price and % Up or Down 5/18/09 - 5/22/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $1.39; Unchanged
Aastrom Biosciences (ASTM) = Cur Price: $0.36; Down -3%
BioTime, Inc. (BTIM) = Cur Price: $2.64; Up 2%
Celgene Corp (CELG) = Cur Price: $39.43; Down -1%
Cytori Therapeutics (CYTX) = Cur Price: $2.88; Up 3%
Geron Corp (GERN) = Cur Price: $6.79; Up 8%
ThermoGenesis (KOOL) = Cur Price: $0.553; Down -3%
Osiris Therapeutics (OSIR) = Cur Price: $12.02; Down -3%
StemCell Inc. (STEM) = Cur Price: $1.68; Down -4%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.13; Down -7%
Athersys Inc. (ATHX) = Cur Price: $0.89; Up 9%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.076; Down -5%
Bioheart Inc. (BHRT) = Cur Price: $0.90; Up 38%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.0048; Down -13%
Cyro-Cell Intl (CCEL.OB) = Cur Price: $1.15; Down -4%
Neuralstem (CUR) = Cur Price: $1.10; Down -7%
International Stem Cell (ISCO.OB) = Cur Price: $0.68; Down -22%
MultiCell Technologies (MCET.OB) = Cur Price: $0.012; Up 14%
Pluristem Therapeutics (PSTI) = Cur Price: $1.16; Down -19%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.065; Unchanged
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.05; Up 2%

Catalyst(s) for the Week:

Nothing has changed from the last few months.

- Again, be on the lookout for further legislative movement to support President Obama's executive order.

- M&A (mergers and acquisitions) activity will be key. It could happen at any time.

Stem Cell Stocks 5/17/09: The Week That Was

2009-05-17T20:18:00.003-04:00

If you remember back to when the market was in its tailspin, one of the only plays that seemed to work were the stem cell stocks. With the overall market currently in a bit of a slide, it was interesting to see if the sector would again be a strong performer. However, nothing much has changed. The only upward movement has come from those individual stocks with news or out of the blue trading momentum.

Top Stem Cell Stock Performer(s) for Last Week:

- International Stem Cell Corp (ISCO.OB) = Up 98% for the week; This stock acted very unusual last week. At one point the stock nearly tripled. Shares spiked on 8 times the average volume on four consecutive trading days. Friday it finally pulled back. All this movement occurred with no news. It looks like a huge short opportunity if you're into that.

Worst Stem Cell Stock Performer(s) for Last Week:

- Bioheart Inc. (BHRT.OB) = Down -24%; Stock has very low volume. Swings of this sort are not uncommon

Stem Cell Stocks Current Price and % Up or Down 5/11/09 - 5/15/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $1.39; Up 5%
Aastrom Biosciences (ASTM) = Cur Price: $0.37; Down -6%
BioTime, Inc. (BTIM) = Cur Price: $2.60; Up 37%
Celgene Corp (CELG) = Cur Price: $39.79; Down -4%
Cytori Therapeutics (CYTX) = Cur Price: $2.80; Up 12%
Geron Corp (GERN) = Cur Price: $6.26; Up 1%
ThermoGenesis (KOOL) = Cur Price: $0.57; Up 6%
Osiris Therapeutics (OSIR) = Cur Price: $12.35; Down -7%
StemCell Inc. (STEM) = Cur Price: $1.75; Up 3%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.14; Up 43%
Athersys Inc. (ATHX) = Cur Price: $0.82; Unchanged
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.08; Up 14%
Bioheart Inc. (BHRT) = Cur Price: $0.65; Down -24%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.0055; Down -4%
Cyro-Cell Intl (CCEL.OB) = Cur Price: $1.20; Down -15%
Neuralstem (CUR) = Cur Price: $1.18; Down -2%
International Stem Cell (ISCO.OB) = Cur Price: $0.87; Up 98%
MultiCell Technologies (MCET.OB) = Cur Price: $0.0105; Up 4%
Pluristem Therapeutics (PSTI) = Cur Price: $1.44; Up 9%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.065; Down -4%
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.049; Up 26%

Catalyst(s) for the Week:

Nothing has changed from the last few months.

- Again, be on the lookout for further legislative movement to support President Obama's executive order.

- M&A (mergers and acquisitions) activity will be key. It could happen at any time.

Stem Cell Stocks 5/10/09: The Week That Was

2009-05-10T21:45:00.003-04:00

Only individual names in the stem cell sector moved this week. Names like GERN and CCEL have impressive charts over the last month, but we have still yet to see that large group move like earlier in the year. Look for there to be continued sporadic movement in the sector.

Top Stem Cell Stock Performer(s) for Last Week:

- Cytori Therapeutics (CYTX) = Up 37% for the week; They announced an agreement by which GE Healthcare will commercialize Cytori’s StemSource® technology in the North American stem cell banking and research markets.

Worst Stem Cell Stock Performer(s) for Last Week:

- ThermoGenesis Corp (KOOL) = Down -19%; Got hammered for reporting 2009 revenue outlook below analyst estimates.

Stem Cell Stocks Current Price and % Up or Down 5/4/09 - 5/8/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $1.32; Down -11%
Aastrom Biosciences (ASTM) = Cur Price: $0.394; Up 4%
BioTime, Inc. (BTIM) = Cur Price: $1.90; Down -2%
Celgene Corp (CELG) = Cur Price: $41.42; Up 5%
Cytori Therapeutics (CYTX) = Cur Price: $2.50; Up 37%
Geron Corp (GERN) = Cur Price: $6.23; Up 22%
ThermoGenesis (KOOL) = Cur Price: $0.54; Down -19%
Osiris Therapeutics (OSIR) = Cur Price: $13.35; Up 7%
StemCell Inc. (STEM) = Cur Price: $1.70; Up 2%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.098; Down -1%
Athersys Inc. (ATHX) = Cur Price: $0.82; Up 1%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.07; Down -5%
Bioheart Inc. (BHRT) = Cur Price: $0.85; Up 9%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.0057; Up 6%
Cyro-Cell Intl (CCEL.OB) = Cur Price: $1.42; Up 15%
Neuralstem (CUR) = Cur Price: $1.21; Up 5%
International Stem Cell (ISCO.OB) = Cur Price: $0.44; Down -6%
MultiCell Technologies (MCET.OB) = Cur Price: $0.0101; Down -8%
Pluristem Therapeutics (PSTI) = Cur Price: $1.32; Down -13%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.068; Down -9%
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.039; Unchanged

Catalyst(s) for the Week:

- Again, be on the lookout for further legislative movement to support President Obama's executive order.

- M&A (mergers and acquisitions) activity will be key. It could happen at any time.

Stem Cell Stocks 5/3/09: The Week That Was

2009-05-03T20:30:00.003-04:00

As expected, the stem cell stocks still did not move this week. A couple of stocks with connections to cancer or the flu moved early in the week, but gave up their gains. Look for there to be continued sporadic movement in the sector.

Top Stem Cell Stock Performer(s) for Last Week:

- Cryo-Cell International (CCEL) = Up 54% for the week; This stock stock has more than doubled in the last 2 1/2 weeks. The rise is began shortly after an earnings report that pointed to a bright future. Look for a pull back shortly.

Worst Stem Cell Stock Performer(s) for Last Week:

- Stem Cell Therapy Intl (SCII) = Down -21% for the week on average volume; No significant news; not out of the ordinary for a penny stock

Stem Cell Stocks Current Price and % Up or Down 4/27/09 - 5/01/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $1.49; Down -2%
Aastrom Biosciences (ASTM) = Cur Price: $0.38; Up 17%
BioTime, Inc. (BTIM) = Cur Price: $1.94; Down -11%
Celgene Corp (CELG) = Cur Price: $39.54; Down -1%
Cytori Therapeutics (CYTX) = Cur Price: $1.82; Up 2%
Geron Corp (GERN) = Cur Price: $5.10; Up 3%
ThermoGenesis (KOOL) = Cur Price: $0.67; Up 14%
Osiris Therapeutics (OSIR) = Cur Price: $12.42; Up 1%
StemCell Inc. (STEM) = Cur Price: $1.66; Up 2%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.099; Down -1%
Athersys Inc. (ATHX) = Cur Price: $0.81; Up 1%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.074; Down -8%
Bioheart Inc. (BHRT) = Cur Price: $0.78; Up 13%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.0054; Down -2%
Cyro-Cell Intl (CCEL.OB) = Cur Price: $1.23; Up 54%
Neuralstem (CUR) = Cur Price: $1.15; Down -3%
International Stem Cell (ISCO.OB) = Cur Price: $0.47; Down -10%
MultiCell Technologies (MCET.OB) = Cur Price: $0.011; Up 10%
Pluristem Therapeutics (PSTI) = Cur Price: $1.52; Up 14%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.075; Down -21%
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.039; Down -5%

Catalyst(s) for the Week:

- Again, be on the lookout for further legislative movement to support President Obama's executive order.

- M&A (mergers and acquisitions) activity will be key. It could happen at any time.

Stem Cell Stocks 4/26/09: The Week That Was

2009-04-26T17:37:00.006-04:00

There has still been no signifcant action with the stem cell stocks. Cancer drugs were hot last week. This week, it's all about the swine flu. As a result, I don't anticipate much upward movement with these stocks this week.

Top Stem Cell Stock Performer(s) for Last Week:

- BioTime, Inc. (BTIM) = Up 25% for the week; This stock rose on word that Broadwood Partners, which is already one of BTIM's large share holders, purchased around 35,000 additional shares.

Worst Stem Cell Stock Performer(s) for Last Week:

- Geron Corp (GERN) = Down -9% for the week; No signicant news; The stock had been on a good run the past few weeks. This just looks like profit taking.

Stem Cell Stocks Current Price and % Up or Down 4/20/09 - 4/24/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Cur Price: $1.52; Up 3%
Aastrom Biosciences (ASTM) = Cur Price: $0.326; Down -8%
BioTime, Inc. (BTIM) = Cur Price: $2.17; Up 24%
Celgene Corp (CELG) = Cur Price: $39.86; Up 4%
Cytori Therapeutics (CYTX) = Cur Price: $1.79; Down -1%
Geron Corp (GERN) = Cur Price: $4.94; Down -9%
ThermoGenesis (KOOL) = Cur Price: $0.59; Down -4%
Osiris Therapeutics (OSIR) = Cur Price: $12.34; Down -4%
StemCell Inc. (STEM) = Cur Price: $1.62; Down -4%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Cur Price: $0.0995; Unchanged
Athersys Inc. (ATHX) = Cur Price: $0.80; Down -1%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.08; Unchanged
Bioheart Inc. (BHRT) = Cur Price: $0.69; Unchanged
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.0057; Down -4%
Cyro-Cell Intl (CCEL.OB) = Cur Price: $0.80; Up 14%
Neuralstem (CUR) = Cur Price: $1.18; Down -2%
International Stem Cell (ISCO.OB) = Cur Price: $0.525; Up 22%
LifeStem International (LSTM.OB) = Cur Price: $0.008; Down -11%
MultiCell Technologies (MCET.OB) = Cur Price: $0.01; Down -5%
Pluristem Therapeutics (PSTI) = Cur Price: $1.33; Unchanged
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.095; Down -5%
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.041; Up 3%

Catalyst(s) for the Week:

The catalyst(s) for the week remain unchanged from last week.

- Again, be on the lookout for further legislative movement to support President Obama's executive order.

- More Mutual fund distribution of funds originally allocated for Genentech. It will take quite a while to redistribute these dollars throughout the biotech sector

- M&A (mergers and acquisitions) activity will be key. It could happen at any time.

Stem Cell Stocks 4/19/09: The Week That Was

2009-04-18T21:49:00.004-04:00

Once again nothing definitive this week for the stem cell stocks. Most the the larger cap stock were up, but most of the smaller cap stocks fell for the week. I am really not expecting much from the stem cells stocks in the very near future. With the news from Dendreon last week, cancer related biotech stocks have become the new hot play. Unless some fresh big news develops in the stem cell space, look for the current trading action to continue.

Top Stem Cell Stock Performer(s) for Last Week:

- ThermoGenesis (KOOL) = Up 19% for the week; The only real news this week was that they appointed a new CEO; I don't think that is enough to maintain this momentum

Worst Stem Cell Stock Performer(s) for Last Week:

- International Stem Cell Corp (ISCO.OB) = Down -14% for the week; No news; A couple of weeks ago this had one of the best charts in the sector. It has significantly brokend down since then

Stem Cell Stocks Current Price and % Up or Down 4/13/09 - 4/17/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Current Price: $1.48; Up 3%
Aastrom Biosciences (ASTM) = Current Price: $0.354; Up 4%
BioTime, Inc. (BTIM) = Current Price: $1.75; Down -9%
Celgene Corp (CELG) = Current Price: $38.30; Down -6%
Cytori Therapeutics (CYTX) = Current Price: $1.81; Up 5%
Geron Corp (GERN) = Current Price: $5.40; Up 10%
ThermoGenesis (KOOL) = Current Price: $0.615; Up 19%
Osiris Therapeutics (OSIR) = Current Price: $12.82; Up 3%
StemCell Inc. (STEM) = Current Price: $1.69; Up 8%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Current Price: $0.0995; Up 2%
Athersys Inc. (ATHX) = Current Price: $0.81; Down -4%
Brainstorm Cell Therapeutics (BCLI.OB) = Current Price: $0.08; Down -10%
Bioheart Inc. (BHRT) = Current Price: Current Price: $0.69; Up 1%
Cord Blood America Inc. (CBAI.OB) = Current Price: $0.0057; Unchanged
Cyro-Cell Intl (CCEL.OB) = Current Price: $0.70; Unchanged
Neuralstem (CUR) = Current Price: $1.20; Down -2%
International Stem Cell (ISCO.OB) = CurrentPrice: $0.43; Down -14%
LifeStem International (LSTM.OB) = Current Price: $0.009; Down -2%
MultiCell Technologies (MCET.OB) = Current Price: $0.0105; Down -10%
Pluristem Therapeutics (PSTI) = Current Price: $1.33; Up 8%
Stem Cell Therapy Intl (SCII.OB) = Current Price: $0.10; Unchanged
Stem Cell Innovations (SCLL.PK) = Current Price: $0.04; Down -13%

Catalyst(s) for the Week:

The catalyst(s) for the week remain unchanged from last week.

- Again, be on the lookout for further legislative movement to support President Obama's executive order.

- More Mutual fund distribution of funds originally allocated for Genentech. It will take quite a while to redistribute these dollars throughout the biotech sector

- M&A (mergers and acquisitions) activity will be key. It could happen at any time.

While the stem cell stocks lag, don't forget to check out my other blog http://yourtradingtips.blogspot.com which provides some insight on ways to make some quick money in the stock market.

Stem Cell Stocks 4/11/09: The Week That Was

2009-04-11T22:49:00.004-04:00

The stem cell stocks were a mixed bag this week. They still seem to be in search of that key news to put the sector back in the spotlight. Overall, the stock market was flat during the week and the stem cell stocks seemed to follow suit. However, I have noticed over the past few weeks that those stem cell stocks that have reported quarterly earnings have responded positively (albeit temporarily).

Top Stem Cell Stock Performer(s) for Last Week:

- Cyro-Cell International (CCEL.OB) = Up 37% for the week; On 4/9/09 CCEL reported Qtr.1 2009 results; The most notable news was that the company stated that prospective clients were up 94% compared to the same period a year ago.

Worst Stem Cell Stock Performer(s) for Last Week:

- Stem Cell Therapy International Inc. (SCII.OB) = Down; -20% for the week; Last week this was the sector's top gainer; It looks like this is just classic profit taking

Stem Cell Stocks Current Price and % Up or Down 4/06/09 - 4/10/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Current Price: $1.43; Up 6%
Aastrom Biosciences (ASTM) = Current Price: $0.34; Down -7%
BioTime, Inc. (BTIM) = Current Price: $1.93; Down -9%
Celgene Corp (CELG) = Current Price: $40.80; Down -3%
Cytori Therapeutics (CYTX) = Current Price: $1.72; Down -5%
Geron Corp (GERN) = Current Price: $4.92; Up 9%
ThermoGenesis (KOOL) = Current Price: $0.518; Down -9%
Osiris Therapeutics (OSIR) = Current Price: $12.42; Down -9%
StemCell Inc. (STEM) = Current Price: $1.57; Down -5%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Current Price: $0.098; Down -7%
Athersys Inc. (ATHX) = Current Price: $0.84; Up 5%
Brainstorm Cell Therapeutics (BCLI.OB) = Current Price: $0.089; Up 5%
Bioheart Inc. (BHRT) = Current Price: Current Price: $0.68; Up 24%
Cord Blood America Inc. (CBAI.OB) = Current Price: $0.0057; Down -14%
Cyro-Cell Intl (CCEL.OB) = Current Price: $0.70; Up 37%
Neuralstem (CUR) = Current Price: $1.23; Down -3%
International Stem Cell (ISCO.OB) = CurrentPrice: $0.50; Up 2%
LifeStem International (LSTM.OB) = Current Price: $0.0092; Down -8%
MultiCell Technologies (MCET.OB) = Current Price: $0.0117; Down -6%
Pluristem Therapeutics (PSTI) = Current Price: $1.23; Down -1%
Stem Cell Therapy Intl (SCII.OB) = Current Price: $0.10; Down -20%
Stem Cell Innovations (SCLL.PK) = Current Price: $0.046; Down -8%

Catalyst(s) for the Week:

The catalyst(s) for the week remain unchanged from last week.

- Again, be on the lookout for further legislative movement to support President Obama's executive order.

- More Mutual fund distribution of funds originally allocated for Genentech. It will take quite a while to redistribute these dollars throughout the biotech sector

- M&A (mergers and acquisitions) activity will be key. It could happen at any time.

Stem Cell Stocks 4/3/09: The Week That Was

2009-04-04T22:51:00.005-04:00

This was another lackluster week for the stem cell stocks. Most of these stocks were slightly down, while once again, the overall market edged higher. In an incredible sign of market strength, the the Dow closed the week over 8000. The stem cell stocks are still not participating in the rally.

Top Stem Cell Stock Performer(s) for Last Week:

- Stem Cell Therapy International Inc. (SCII.OB) = Up 67% for the week; Last week the company announced its first new product, a cosmetic face cream made with stem cells. The cream is said to rejuvenate the skin and provide excellent health for facial tissues. The market seemed to be impressed.

Worst Stem Cell Stock Performer(s) for Last Week

- Cord Blood America (CBAI.OB) = Down -23% for the week; After a brief rise, the stock appears to be under selling pressure after it was voted to allow management to increase the number authorized common shares.

Stem Cell Stocks Current Price and % Up or Down 3/30/09 - 4/03/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Current Price: $1.35; Down -1%
Aastrom Biosciences (ASTM) = Current Price: $0.365; Down -9%
BioTime, Inc. (BTIM) = Current Price: $2.11; Unchanged
Celgene Corp (CELG) = Current Price: $42.15; Down -8%
Cytori Therapeutics (CYTX) = Current Price: $1.81; Up 1%
Geron Corp (GERN) = Current Price: $4.51; Down -8%
ThermoGenesis (KOOL) = Current Price: $0.57; Down -5%
Osiris Therapeutics (OSIR) = Current Price: $13.66; Down -5%
StemCell Inc. (STEM) = Current Price: $1.66; Down -8%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Current Price: $0.105; Down -16%
Athersys Inc. (ATHX) = Current Price: $0.80; Down -8%
Brainstorm Cell Therapeutics (BCLI.OB) = Current Price: $0.085; Down -8%
Bioheart Inc. (BHRT) = Current Price: Current Price: $0.55; Down -8%
Cord Blood America Inc. (CBAI.OB) = Current Price: $0.0066; Down -23%
Cyro-Cell Intl (CCEL.OB) = Current Price: $0.512; Down -17%
Neuralstem (CUR) = Current Price: $1.27; Up 20%
International Stem Cell (ISCO.OB) = CurrentPrice: $0.49; Down -2%
LifeStem International (LSTM.OB) = Current Price: $0.01; Up 33%
MultiCell Technologies (MCET.OB) = Current Price: $0.0125; Down -7%
Pluristem Therapeutics (PSTI) = Current Price: $1.24; Down -8%
Stem Cell Therapy Intl (SCII.OB) = Current Price: $0.125; Up 67%
Stem Cell Innovations (SCLL.PK) = Current Price: $0.005; Down -17%

Possible Catalyst(s) for the Week:

The catalyst(s) for the week remain unchanged from last week.

- Again, be on the lookout for further legislative movement to support President Obama's executive order.

- More Mutual fund distribution of funds originally allocated for Genentech. It will take quite a while to redistribute these dollars throughout the biotech sector.

- M&A (mergers and acquisitions) activity will be key. It could happen at any time.

Ending Thoughts:

The stem cell stocks definitely need to get moving in the next couple of weeks to maintain any level of relevancy. With the market bulling its way forward and so many other sectors recovering with such strength, these stocks are in desperate need of a charge.

Stem Cell Stocks 3/28/09: The Week That Was

2009-03-27T22:55:00.007-04:00

This was a nice bounce back week for the stem cell stocks. For a quite a bit of time, it appeared that the market had forgotten this entire sector, but things finally seemed to take a turn for the better. Nothing really earth shattering happened to cause the change in sentiment. As result, I can only conclude that it was the stem cell stocks' turn to catch up.

I recently decided to make a modification to this blog. Because many of the stem cell stocks have technically detached from the previous pivot point of 1/23/09, I've decided to now track each stock based on their weekly performance.

Top Stem Cell Stock Performer(s) for Last Week:

- Advanced Cell Technology (ACTC.OB) = Up 67% for the week; If you remember, ACTC.OB was the worst performer last week. This week there was no major news, but as I figured, it bounced right back.

Worst Stem Cell Stock Performer(s) for Last Week:

- Osiris Therapeutics (OSIR) = Down -21% for the week; This tanked due to the company discontinuing a phase III Crohn's Disease trial.

- Stem Cell Innovations (SCLL.PK) = Down -20% for the week; Another one of those stocks significantly beaten in the stem cell sector the past 3 weeks on no news. It seems to be following a similar trend as ACTC.OB. I eventually think this trend should reverse.

Stem Cell Stocks Current Price and % Up or Down 3/23/09 - 3/27/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Current Price: $1.36; Up 9%
Aastrom Biosciences (ASTM) = Current Price: $0.40; Up 14%
BioTime, Inc. (BTIM) = Current Price: $2.10; Up 2%
Celgene Corp (CELG) = Current Price: $46.04; Up 1%
Cytori Therapeutics (CYTX) = Current Price: $1.80; Up 5%
Geron Corp (GERN) = Current Price: $4.89; Up 20%
ThermoGenesis (KOOL) = Current Price: $0.60; Up 18%
Osiris Therapeutics (OSIR) = Current Price: $14.32; Down -21%
StemCell Inc. (STEM) = Current Price: $1.81; Up 21%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.OB) = Current Price: $0.125; Up 67%
Athersys Inc. (ATHX) = Current Price: $0.87; Up 10%
Brainstorm Cell Therapeutics (BCLI.OB) = Current Price: $0.09; Unchanged
Bioheart Inc. (BHRT) = Current Price: Current Price: $0.60; Up 2%
Cord Blood America Inc. (CBAI.OB) = Current Price: $0.0086; Up 23%
Cyro-Cell Intl (CCEL.OB) = Current Price: $0.62; Up 7%
Neuralstem (CUR) = Current Price: $1.06; Up 6%
International Stem Cell (ISCO.OB) = CurrentPrice: $0.50; Up 6%
LifeStem International (LSTM.OB) = Current Price: $0.0075; Up 15%
MultiCell Technologies (MCET.OB) = Current Price: $0.0135; Unchanged
Pluristem Therapeutics (PSTI) = Current Price: $1.35; Up 16%
Stem Cell Therapy Intl (SCII.OB) = Current Price: $0.08; Unchanged
Stem Cell Innovations (SCLL.PK) = Current Price: $0.006; Down -20%

Possible Catalyst(s) for the Week:

- Again, be on the lookout for further legislative movement to support President Obama's executive order.

- More Mutual fund distribution of funds originally allocated for Genentech. It will take quite a while to redistribute these dollars throughout the biotech sector.

- M&A (mergers and acquisitions) activity will be key. It could happen at any time.

Ending Thoughts:

My gut feeling tells me that the market will trade higher on Monday, but will slide lower the rest of the week. The quarter is coming to an end and after such thunderous gains, the market may be looking to take a breather. If this does take place, DOW 8000 becomes the new technical point of resistance. It's hard to determine where exactly this leaves the stem cell stocks, but be mindful that a pullback may occur.

Stem Cell Stocks 3/22/09: The Week That Was

2009-03-21T22:57:00.007-04:00

As a whole, this was not a good week for the stem cell stocks. Most were down 5% - 10%. The smaller caps were hit particularly hard. It has been tough to find the stem cell stocks' place in this current market. Overall, the market is in rally mode, but these stocks just have not been a part of the run. Right now, all the large cap stocks that we track are below its price prior to our reference date of 1-23-09.

Top Stem Cell Stock Performer(s) for Last Week:

- Athersys (ATHX) = Up 41% for the week; This stock rose after it reported its 2008 year end earnings. Losses narrowed, but investors seemed to be encouraged that the company is moving ahead with its adult stem cell therapy Multistem. After spiking after the announcement on 1-23-09, ATHX dropped precipitously for a month and a half. This was the first sign of a possible reversal.

Worst Stem Cell Stock Performer(s) for Last Week:

- Advanced Cell Technology Inc. (ACTC.PK) = Down -40% for the week; There has been no news and the volume has been average. Although the drop has been substantial, there's not a lot of force behind it. Bargain hunters will probably scoop this up quickly next week.

Stem Cell Stocks Current Price and % Up or Down Since the First Rally on 1/23/09
Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Current Price: $1.25; Down -13%
Aastrom Biosciences (ASTM) = Current Price: $0.35; Down -32%
BioTime, Inc. (BTIM) = Current Price: $2.05; Down -2%
Celgene Corp (CELG) = Current Price: $45.52; Down -7%
Cytori Therapeutics (CYTX) = Current Price: $1.72; Down -46%
Geron Corp (GERN) = Current Price: $4.08; Down -22%
ThermoGenesis (KOOL) = Current Price: $0.51; Down -6%
Osiris Therapeutics (OSIR) = Current Price: $18.04; Down -4%
StemCell Inc. (STEM) = Current Price: $1.50; Down -30%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.PK) = Current Price: $0.075; Down -38%
Athersys Inc. (ATHX) = Current Price: $0.79; Up 16%
Brainstorm Cell Therapeutics (BCLI.OB) = Current Price: $0.0925; Down -8%
Bioheart Inc. (BHRT) = Current Price: Current Price: $0.59; Down -25%
Cord Blood America Inc. (CBAI.OB) = Current Price: $0.007; Up 84%
Cyro-Cell Intl (CCEL.OB) = Current Price: $0.58; Up 26%
Neuralstem (CUR) = Current Price: $1.00; Down -30%
International Stem Cell (ISCO.OB) = CurrentPrice: $0.47; Up 62%
LifeStem International (LSTM.OB) = Current Price: $0.0065; Up 67%
MultiCell Technologies (MCET.OB) = Current Price: $0.0135; Up 214%
Pluristem Therapeutics (PSTI) = Current Price: $1.16; Up 82%
Stem Cell Therapy Intl (SCII.OB) = Current Price: $0.0925; Up 50%
Stem Cell Innovations (SCLL.PK) = Current Price: $0.0075; Up 36%

Possible Catalyst(s) for the Week:

- Again, be on the lookout for further legislative movement to support President Obama's executive order.

- Analysis upgrades are coming. These stocks are just getting too cheap.

Although the catalysts above could help cause the stem cell stocks to end their current slide, I don't think you'll see another huge move until one of the companies in the sector get's bought out or a hostile takeover is made public. Because stem cell stocks focus on research, very few if any are going to have earnings. When a stock doesn't have earnings, it is very difficult for the market to accurately assign it a value. Until M&A activity happens, don't expect any monster pops.

The main reason I do this blog and others, is so we can call make some money. You can also check out another blog I've started called "The Perfect Stock" at http://theperfectstock.blogspot.com/ . The site picks a stock covering all sectors that is perfectly setup both fundamentally and technically. Check it out when you get a chance.

3-17-09 Will the Stem Cell Stocks Participate?

2009-03-17T20:57:00.007-04:00

The stock market continues to press upward, but many people are wondering why the stem cell stocks haven't participated in the rally. I feel that it is just a matter of time. There are so many sectors in the market that have really been beaten up over the last 6 to 8 months. Right now, it is their time to shine. The "Financials" and "Auto Suppliers" are the hot sectors. These stocks were literally thrown away and left for dead. Now, it's an entirely different story. When you have multiple daily runs of 20% - 60%, stock traders and investors will gravitate to what's hot and ride the momentum. Citigroup is up around 150% in a little over a week. Auto supplier stocks like Hayes Lemmerz Intl (HAYZ) and Tenneco (TEN) are up 300% - 400% during the same time frame. Technically, the stem cell stocks have been one of the more successful sectors despite the accelerated downturn of the stock market. Every sector at some point has their day in the sun.

We will see what the rest of the week will hold, but maybe today, 3-17-09, was the start of the the stem cell rally. Most of the large cap stem cell stocks moved upward pretty hard today (STEM was up 16%). The smaller caps and penny stem cell stocks continued their slide, but history has shown that these stocks typically follow the large caps. At the beginning of a run, it is rare that they move simultaneously higher with no news. Keep a eye on the stem cell sector the rest of the week. The market looks poised to continue higher. Let's see if the stem cell stocks catch up.

Stem Cell Stocks 3/14/09: The Week That Was

2009-03-14T15:33:00.020-04:00

The stem cells stocks began the week with blaze, but ended rather anticlimactically with just a smolder. Most of the sector ended positive for the week, but most investors and/or stock traders were disappointed that gains from last Monday morning didn't hold.

Top Stem Cell Stock Performer(s) for Last Week:

- Pluristem Therapeutics (PSTI) = Up 44% for the week; This low floater is now getting a lift after the hangover from its secondary offering a little over a month ago.

- BioTime, Inc (BTIM) - Up 30% for the week; The market appears to understand that this is one of the few stem cell stocks that will directly benefit from Obama's executive order to unfreeze human embryonic stem cell federal funding. Click here for blog addressing this in more detail

Worst Stem Cell Stock Performer(s) for Last Week:

- Cytori Therapeutics (CYTX) = Down -19% for the week; This stock got a big pop from the Obama executive order as did many of the other stem cell stocks. However, it plummeted shortly after their secondary offering was announced. The dilution appears pretty significant (36% after all warrants are exercised) and the market punished them accordingly. The company desperately needed the money and is now near its all-time low share price. With all that being said, the company still has great technology and a solid future now that it has an infusion of capital. Looks to me like a great buying opportunity from here at any sign of a trend reversal.

Stock to Watch:

- International Stem Cell Corp (ISCO.OB) - Out of all the stem cell stocks, this one has by far the best looking chart and momentum. The month of February was just "noise" in what appears to be a steady upward trend. Also, volume is steadily increasing despite the rise in share price. This is always a good sign for stocks $0.25 - $1.00 per share. I think this stock is becoming a favorite because the company addresses one of the issues that is now at the forefront of Obama's executive order. Supposedly, human embryonic stem cells federal funding was initially suspended due to concerns over embryos being destroyed in the testing process. ISCO.OB was the first company to perfect a method of creating human stem cells from unfertilized eggs. Their unique human stem cells, called "parthenogenetic" stem cells, have ethical advantages since they do not require the use of fertilized embryos. The stock was consistently priced around $3/share during the first half of 2007 until it mysteriously dropped. With the current environment being so strong for stem cell stocks, it could have quite a run. See below for ISCO.OB's chart:

Stem Cell Stocks Current Price and % Up or Down Since the First Rally on 1/23/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Current Price: $1.33; Down -8%

Aastrom Biosciences (ASTM) = Current Price: $0.40; Down -23%

BioTime, Inc. (BTIM) = Current Price: $2.21; Up 6%

Celgene Corp (CELG) = Current Price: $48.20; Down -2%

Cytori Therapeutics (CYTX) = Current Price: $1.88; Down -41%

Geron Corp (GERN) = Current Price: $4.36; Down -16%

ThermoGenesis (KOOL) = Current Price: $0.46; Down -15%

Osiris Therapeutics (OSIR) = Current Price: $18.13; Down -4%

StemCell Inc. (STEM) = Current Price: $1.65; Down -23%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.PK) = Current Price: $0.13; Up 4%

Athersys Inc. (ATHX) = Current Price: $0.56; Down -18%

Brainstorm Cell Therapeutics (BCLI.OB) = Current Price: $0.097; Down -3%

Bioheart Inc. (BHRT) = Current Price: Current Price: $.70; Down -11%

Cord Blood America Inc. (CBAI.OB) = Current Price: $0.009; Up 137%

Cyro-Cell Intl (CCEL.OB) = Current Price: $0.60; Up 30%

Neuralstem (CUR) = Current Price: $0.94; Down -34%

International Stem Cell (ISCO.OB) = CurrentPrice: $0.54; Up 86%

LifeStem International (LSTM.OB) = Current Price: $0.009; Up 131%

MultiCell Technologies (MCET.OB) = Current Price: $0.0107; Up 149%

Pluristem Therapeutics (PSTI) = Current Price: $1.55; Up 144%

Stem Cell Therapy Intl (SCII.OB) = Current Price: $0.08; Up 60%

Stem Cell Innovations (SCLL.PK) = Current Price: $0.0095; Up 73%

Possible Catalyst for the Week:

- Be on the lookout for further legislative movement to support President Obama's executive order. It may not cause the stem cell stocks to explode like early last week, but it should keep the sector noteworthy and stock traders happy enough support future gains.

- The market appears to have changed its sentiment (at least temporarily). The fact that the S&P 500 bounced off the 660's and closed above 750 for the week is a very good sign from a technical standpoint. If this is a true bear market rally as many believe, there's possibly another 50 points still on the table until we have some distinctive profit taking. I see no reason why the stem cell stocks won't move with the rest of the market.

- As mentioned before, I expect to see more analyst upgrades since many of these stocks have now retraced and bottomed from their fast rise in late January.

- With the Roche/ Genentech Deal finally over, many experts feel that a lot of Biotech hedge fund money will be transferred to other Biotech names. This could bode well for larger cap stem cell stocks like Celgene (up 15% to 20% last week), StemCells Inc., and Geron Corp.

Embryonic Stem Cells: Which Stocks Directly Benefit from Obama's Decision?

2009-03-11T20:44:00.009-04:00

The excitement of the executive order issued by President Obama allowing companies to receive federal funding for human embryonic stem cells research has brought a lot of new investor interest to the sector. All the stem cell stocks received a boost because the overall sentiment of the group became more positive. However, this post is to specifically address a question with these stocks that everyone seems to keep asking, "Which stem cell stocks directly benefit from this news?"

Early in the week, the answer to this question was not really all that important. To be honest, I don't think anybody cared as long as their stock kept going up. Now that some of the euphoria has died down, investors are more apt to gravitate to quality and relevancy as oppose to the "low floater". There are three stem cell stocks that I have found that directly benefit from federal funding opportunities:

Gern Corporation (GERN) - This stem cell stock received the go ahead for the first government-approved clinical trial testing human embryonic stem cells on people. Studies of this nature typically require multiple trials and can be very expensive to perform. Federal funding would soften the company's cash burn and lessen the need for partnerships and share holder dilution.

Advanced Cell Technology (ACTC.PK) - They have hundreds of patents and developed techniques to obtain embryonic stem cells while leaving the embryos functionally intact. Studies bolstering the significance of these techniques, which could act as the key cog in a potential scientific breakthrough, were requested to be funded by the federal government in 2007. However, they were denied simply due to a lack of political favor. Also, with this new funding available, new groups will be interested in doing research in the field. As a result of all the patents Advanced Cell Technology hold, they are nicely positioned for royalties.

BioTime, Inc (BTIM) - CEO, Dr. Michael West is one of the pioneers of the human stem cells industry. He was the founder of Geron Corp and also worked at Advanced Cell Technology. BioTime owns a subsidiary called Embryome Sciences, Inc. Part of their business involves marketing and selling new embryonic stem cell lines to universities and pharmaceutical companies. Fresh funding should supply potential customers of Embryome Sciences lots of cash to make this essential purchase.

Stem Cell Company Stocks 3/7/09: Updated 3/9/09

2009-03-06T22:28:00.022-05:00

What a wild day to say the least for the stem cell stocks! There were upwards of 175% gains during the first hour of trading (MCET.OB getting the honor of having the highest percentage intraday gain). Unfortunately, things tailed off quite a bit as soon as President Obama spoke about the executive order. It's was a classic "sell the news", which left many people disappointed if they didn't take profits. The overall stock market inching further down didn't help either. However, all is not yet lost.

This sell off may just be the ammunition that "big money" sitting on the sidelines needs. No professional would dare buy a stock the day of a 40% - 100% gap up at the open. This entire day was about short seller covering and retail stock buyers and sellers like you and me. I suspect that very few institutional buys have been initiated yet. The smart ones won't get in until there's a nice balance of these stocks falling far enough to have an appealing entry while at the same time technically maintaining upward momentum. It will be at this point when you'll start seeing multiple analyst upgrades. There's already been one today (see comments).

The next couple of days should tell a lot. The hope is that we get a maintainable, steady rise, but don't be discouraged if there's a gap up again tomorrow followed by some selling. The top picks continue to be GERN, ACTC.PK, and STEM for the long term.

--------------------------------------------------------------------------

3-7-09

Prior to the close of Friday's market, nothing special happened again this week for the Stem Cell stocks. A few were flat but the majority remained down. However, after weeks of seemingly getting pounded, there finally appears to be a light at the end of the tunnel. Most names in the sector exploded 3/6/09 after hours in upwards of 80% on news that President Obama will sign an executive order to allow federal funding for human embryonic stem cell research. What's amazing is that these huge moves are taking place with the larger cap stem cell stocks. The unusual spike signifies that the sector has been heavily shorted after such an impressive run up ending the beginning of February. There will be some tremendous money making opportunities to begin the week so hopefully you've been holding tight or you've recently made some timely buys. Forget about trying to figure out which stocks deal directly with human embryonic stem cells. Every company in the sector will get lumped together (see the last stem cell and infrastructure rallies for proof). Let's take a look at some possible game plans Monday:

Game plan 1 - As far as the large cap stem cell stocks, there will probably be significant selling in Monday's pre-market and the first 30 minutes to an hour of trading. As a result, I'd be very surprised if a stock like ASTM actually opens with the 82% gain currently showing after hours. If you already have a position in the stock, you can either sell with the herd or hang tight and hope for a full day or multi-day run. If the market as a whole is in rally mode, it may be worth holding on. However, be careful because the market could be similar to last Friday's with a first hour suckers rally to start the session. If you decide to chase (although I wouldn't recommend it with the larger caps) I'd stick with GERN, STEM, ASTM, CYTX, and KOOL. Look to start a position after a probable MM shakeout around 10AM.

Game plan 2 - If the gains with the large cap stocks are as significant as the after hours forecast, the small caps should really explode. If you are looking to buy into the sector early Monday, the small caps may be the safest bet. Penny stock chasers will pump the likes of CBAI.OB, MCET.OB, ACTC.PK, etc. like there is no tomorrow. The sentiment of every penny stock forum and message board I've seen this weekend has been to "load the boat" with stem cell stocks. All of these stocks should do well and I'd load up first thing in the morning. Typically, it's better to buy penny stocks at 9:30AM because the gap ups are not as extreme due to the fact that there is very little pre-market activity to significantly drive up the price. I would particularly be on the lookout for stem cell stock low floaters MCET.OB, LSTM.OB (despite the reservations people have if it is really still a stem cell company) and PSTI purely based on recent history. The super run MCET.OB had a little over a month ago is still fresh in the minds of many. I'd expect expect close to a repeat performance.

Game plan 3 - Don't forget 2nd and 3rd day singular stock moves. If you see a particular stock is being left out in Monday's run for no reason, it might be a good idea to initiate a position. It's hard for every stock in a sector to go up significantly on the same day. There are simply too many "pile jumpers" in the stock trading world. PSTI was one the last big moving stocks after GERN's big announcement so keep your eyes open.

Game plan 4 - If you are into the buy and hold theory and want to invest long term, stick with the best of breed names like GERN and STEM. If you want the safest investment with the biggest potential to hit the jackpot, own ACTC.PK.

Top Stem Cell Stock Performer(s) for Last Week:

- Stem Cell Innovations (SCLL.PK) = Up 20% for the week; There has been no news. So, based on the solid volume, it looks like the sellers have just dried up and there is slow steady accumulation.

Worst Stem Cell Stock Performer(s) for Last Week:

- Geron Corp (GERN) = Down -14% for the week; It's obviously being shorted to no end. Shortsqueeze.com says that 22% of the float is being shorted. It's still a good company, but it's being dragged down with the rest of the market. However, the short squeeze will be explosive!

Stem Cell Stocks Current Price and % Up or Down Since the First Rally on 1/23/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Current Price: $1.20; Down -17%
Aastrom Biosciences (ASTM) = Current Price: $0.33; Down -36%
BioTime, Inc. (BTIM) = Current Price: $1.70; Down -19%
Celgene Corp (CELG) = Current Price: $41.16; Down -16%
Cytori Therapeutics (CYTX) = Current Price: $2.31; Down -28%
Geron Corp (GERN) = Current Price: $3.87; Down -26%
ThermoGenesis (KOOL) = Current Price: $0.40; Down -26%
Osiris Therapeutics (OSIR) = Current Price: $18.01; Down -4%
StemCell Inc. (STEM) = Current Price: $1.38; Down -36%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.PK) = Current Price: $0.11; Down -8%
Athersys Inc. (ATHX) = Current Price: $0.58; Down -15%
Brainstorm Cell Therapeutics (BCLI.OB) = Current Price: $0.10; Down -5%
Bioheart Inc. (BHRT) = Current Price: Current Price: $1.00; Up 27%
Cord Blood America Inc. (CBAI.OB) = Current Price: $0.0089; Up 134%
Cyro-Cell Intl (CCEL.OB) = Current Price: $0.54; Up 17%
Neuralstem (CUR) = Current Price: $0.86; Down -40%
International Stem Cell (ISCO.OB) = CurrentPrice: $0.45; Up 55%
LifeStem International (LSTM.OB) = Current Price: $0.01; Up 156%
MultiCell Technologies (MCET.OB) = Current Price: $0.0099; Up 130%
Pluristem Therapeutics (PSTI) = Current Price: $1.08; Up 70%
Stem Cell Therapy Intl (SCII.OB) = Current Price: $0.06; Up 20%
Stem Cell Innovations (SCLL.PK) = Current Price: $0.009; Up 64%

Possible Catalyst for the Week:

- It was announce just before the close of the market on Friday that President Obama will sign an executive order on Monday rolling back restrictions on federal funding of human embryonic stem cells research. GERN is up 40% and STEM is up 67% during Friday's after hours. This is a dead giveaway for a major short squeeze.

-5th Annual Stem Cell Research & Therapeutic Conference - runs March 9-10, 2009; http://www.gtcbio.com/conferenceDetails.aspx?id=145 ; A different stem cell conference last month got a lot of coverage from news and television outlets and the stocks in the sector responded strongly.

- Most people are expecting a bear market rally this coming week. We are very close to a key technical support level in the S&P. Also, there will be a lot of positive speculation leading up to a hearing on 3/12/09 regarding "Mark to Market" Accounting, which could help the financial sector. I'd suspect that many of the beaten down sectors particularly with strong fundamentals like the stem cells stocks will get a significant boost.

- Look for a series of analyst upgrades. They are always late to the party and are just looking to boost the value of their own investments. It could help the stem cell stocks though.

Stem Cell Company Stocks 3/3/09

2009-03-03T20:18:00.007-05:00

Geron Corp (GERN), the flagship stock of the stem cell sector had an exceptional day today (8% move up) after a series of down days to numerous to count. Also, there have been a couple of nice press releases so far this week from Aastrom Biosciences (ASTM) and Pluristem Therapeutics (PSTI), which caused 30% to 40% increases in their stock prices. ASTM had the FDA remove a clinical hold on a heart study involving the use of a mixed-cell product. PSTI announced FDA clearance for the first-in-human placenta-derived stem cell study. However, despite these events, the sector overall has basically been a mixed bag.

More Chartology

As I've stated in previous blogs, the fate of Stem Cells stocks appears to lie with the general market. It looks like the psychological barrier of DOW 7000 proved not to be the mark which leads to the market's technical bounce. Many thought this might be the number because it represented approximately a 50% retracement of the its high. So, if DOW 7000 isn't the number, what is?

First, let me state why I think these technical points are important. With practically all stocks sliding, there has to come a point where the selling stops. Trading has become more and more electronic and now many hedge funds and investment brokerages use computer base quantitative models to initiate buying and selling. As a result, everyone is waiting for that key number in the traditional indexes to hit. Once it does hit, the flood gates will open. Let's look at the chart below of the S&P500:

According to the chart, the next level of support is around 650 from back in 1996. Currently, we sit at 696 so the 650's represents about a 7% decline from where we are now. Because of the stem cell stocks fundamentals, they should rebound strongly with the market. Unfortunately, if this doesn't hold, the next support area is 450. There's an awful lot of pain ahead of us if we reach those levels.

Stem Cell Company Stocks 3/1/09

2009-03-01T14:09:00.008-05:00

Stem Cell Stocks 2/23/09 - 2/27/09 the Week That Was

These stocks continued to struggle last week. Initially, the larger caps were slightly safer as far as protecting against huge losses, but even those are making huge turns south. For the first time since we've followed these stocks, all the large caps are below their share price prior to Geron Corp's pivotal announcement on 1/23/09. The past 2 or 3 weeks where there was only one up day a week has become commonplace. I would not be to eager to go out and buy anything in this sector until there is some sort of reversal in the trend. See below for a summary of last week's stem cell stock moves.

Top Stem Cell Stock Performer(s) of the Week:
- International Stem Cell Corp (ISCO) = Up 11% for the week; Up 52% the last two trading days on higher than normal trading volume; Since there was no news associated with late week move, I wouldn't read too much into the price spike. I definitely would not recommend chasing.

Worst Stem Cell Stock Performer(s) of the Week:
- StemCells, Inc (STEM) = Down -20% for the week; Pretty much representative of the entire stem cell sector. Down 4 out of the 5 trading days. Being dragged down with the rest of the market

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Current Price: $1.11; Down -23%
Aastrom Biosciences (ASTM) = Current Price: $0.37; Down -28%
BioTime, Inc. (BTIM) = Current Price: $1.68; Down -20%
Celgene Corp (CELG) = Current Price: $44.73; Down -9%
Cytori Therapeutics (CYTX) = Current Price: $2.76; Down -14%
Geron Corp (GERN) = Current Price: $4.60; Down -12%
ThermoGenesis (KOOL) = Current Price: $0.48; Down -12%
Osiris Therapeutics (OSIR) = Current Price: $17.90; Down -9%
StemCell Inc. (STEM) = Current Price: $1.56; Down -26%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.PK) = Current Price: $0.12; Unchanged
Athersys Inc. (ATHX) = Current Price: $0.60; Down -12%
Brainstorm Cell Therapeutics (BCLI.OB) = Current Price: $0.09; Down -10%
Bioheart Inc. (BHRT) = Current Price: Current Price: $1.01; Up 28%
Cord Blood America Inc. (CBAI.OB) = Current Price: $0.0101; Up 166%
Cyro-Cell Intl (CCEL.OB) = Current Price: $0.60; Up 30%
Neuralstem (CUR) = Current Price: $0.94; Down -34%
International Stem Cell (ISCO.OB) = CurrentPrice: $0.50; Up 72%
LifeStem International (LSTM.OB) = Current Price: $0.0088; Up 126%
MultiCell Technologies (MCET.OB) = Current Price: $0.0115; Up 167%
Pluristem Therapeutics (PSTI) = Current Price: $1.05; Up 65%
Stem Cell Therapy Intl (SCII.OB) = Current Price: $0.06; Up 20%
Stem Cell Innovations (SCLL.PK) = Current Price: $0.0075; Up 36%

Possible Catalyst for the Week:

- Again there is the potential for President Obama to give an executive order to allow funding for stem cell research; If this happens during this continual downward trend in the market the pop will be short lived
- Much like last week, the catalyst is a technical bounce in the overall market. The DOW is only about 60pts from 7000. If the market tanks heavy and hard (down 250 - 300 pts) on Monday to about 6800, I would expect a hard intra-day reversal. If you are quick with the trigger, you can make a lot of money.

Stem Cell Company Stocks - Updated 2/25/09

2009-02-21T16:38:00.026-05:00

It's been an interesting week thus far with the stem cells stocks. After 3 days it's still not clear if these stocks are continuing to decline, leveling out, or reversing back upward. After witnessing Tuesday's action led by GERN and STEM where many of the larger cap stem cell stocks rose, today's action was fairly predictable. Since, these stocks have been on investors' radar, the large caps have led and the small caps have followed. The same occurred today. Many of the stocks that didn't participate in Tuesday's run, made up for it today. For example, after declines 8 of the last 9 days, CBAI.OB spike for 38% gain. Meanwhile, the large caps pulled back again.

First, I think Thursday's action is especially critical for the large caps. If it looks like names like GERN and STEM are getting hammered again, I would recommend you strongly consider exiting your position and then think about retooling if we reach that 6800 - 7000 level in the DOW. If the Stem cell action appears positive, it signals the next leg up.

As far as the small caps, be very careful. Recently, the stock movements of this group have been very "pennylike" (and I mean that in a bad way). CBAI.OB in particular should be watched very closely. Because it finished the end of the day Wednesday 2/25/09 so strongly, I'd expect a gap up Thursday morning. The buyers will probably pour in the first 5 minutes or so of trading based the stock's history the last few months. Shortly thereafter, someone will place a fairly large sell order to take profits and one of the MM's (probably NITE) will sharply drop the price. At this point, the stock could completely turn south giving up all of its gains as stops are taken out and others panic sell. On the other side of the coin, there could be so many buyers that the dip is temporary and the stock steadies into a nice intra-day incline. Overall though, the fate of the small caps lie with large caps. If the large caps respond positively, the small caps should follow.

----------------------------------------------------------

Wow! The week of 2/16/09 - 2/20/09 was a crushing one for stem cell stocks. Aside from one sparkling day thanks to CNBC's pump of the Stem Cell Summit, this was a week to forget. Thankfully, there were only 4 trading days. After rummaging through the carnage, it appears at first glance that there may be no survivors and that the stem cell stocks are done. The stock market as a whole is in free fall and the strength of its downward slide is carrying almost every sector down with it (the exception being Gold and Silver). Dow 7000 is right in our mist and to be quite honest, I don't see a market bounce until we hit the 6900 -7000 range. Right now, that appears to be the psychological barrier that everyone seems to be waiting for. Until we get there, I see everything going lower. Fundamentally, I think stem cell stocks are still a good play, but in today's blog, I wanted to focus on where they are technically.

After analyzing the charts of several stem cell stocks, it is still anybody's guess what will happen to them next. First, let me make a clarification. I do not consider myself to be a true stock technician. I'm not someone who looks at bollinger bands, moving averages, and candles. In my opinion, looking at basic linear trends is a much simpler approach and is just as effective. Let first look at Geron Corp (GERN)

This chart of GERN is indicative of many of the relatively larger cap stem cell stocks. Notice the steady 2 month rise beginning around the end of November. Then, all of a sudden there was an explosion on 1/23/09 with Geron's well publicized announcement. The quick rise was unsustainable and a precipitous drop happened shortly thereafter. Presently, the stock appears to be at a crossroads. The arrows show the two possible directions in which this stock can go. It could continue on it's downward path, in which case you cut your losses and wait for a new entry point. However, the spike and drop the last month could just be "noise" or "gap filling" as GERN continues its slow ascent. If we dip to that key level in the DOW of 7000 quickly, a reversal could occur and the positive chart trend remains intact. If it takes 2 to 3 weeks for us to drop another 350 to 400 points, it may be too much to overcome for a bounce back.

Let's look at MCET:

MCET's chart is indicative of many of the smaller cap stem cell stocks. The picture this chart paints is a little more negative and more defined than GERN's. This chart is setting up like a classic penny stock chart. A textbook penny stock consists of building a long term base and then a quick spike. The quick spike is usually followed by a return to the previous or new base building area. MCET seems to be back in a base building mode. However, the bright side is that the base building area appears to be at a higher level than the previous one and if things continue, it's a waiting game until the next super spike happens. Just be sure to sell at the top when it happens.

----------------------------------------------------------------

Stem Cell Stocks 2/16/09 - 2/20/09 the Week That Was

A new stock was added to the list of stocks followed on http://tradingstemcells2009.blogspot.com/ . The stock is Cytori Therapeutics (CYTX). It should have been on the list to begin with. Purely an oversight on my part.

Top Stem Cell Stock Performer(s) of the Week:

- Celgene Corp(CELG) = Up 3% ; It appears the only safe haven is in this diversified large cap. You won't get big gains, but you won't get huge losses either

Worst Stem Cell Stock Performer(s) of the Week:

- Ariad Pharmaceuticals (ARIA) = Down -42%; Had an explosive run up into earnings; Looks like profit takers and shorters are viciously taking this one down

- Athersys, Inc. (ATHX) = Down -31%; Another stem cell high flyer finally taking its lumps

Stem Cell Stocks Performance Since 1/23/09:

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Current Price: $1.48; Up 3%

Aastrom Biosciences (ASTM) = Current Price: $0.45; Down -13%

BioTime, Inc. (BTIM) = Current Price: $1.64; Down -22%

Celgene Corp (CELG) = Current Price: $53.99; Up 10%

Cytori Therapeutics (CYTX) = Current Price: $3.33; Up 4%

Geron Corp (GERN) = Current Price: $5.33; Up 2%

ThermoGenesis (KOOL) = Current Price: $0.55; Unchanged

Osiris Therapeutics (OSIR) = Current Price: $19.04; Up 1%

StemCell Inc. (STEM) = Current Price: $1.96; Down -10%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.PK) = Current Price: $0.155; Up 29%

Athersys Inc. (ATHX) = Current Price: $0.67; Down -1%

Brainstorm Cell Therapeutics (BCLI.OB) = Current Price: $0.09; Down -13%

Bioheart Inc. (BHRT) = Current Price: Current Price: $1.03; Up 30%

Cord Blood America Inc. (CBAI.OB) = Current Price: $0.0102; Up 168%

Cyro-Cell Intl (CCEL.OB) = Current Price: $0.59; Up 28%

Neuralstem (CUR) = Current Price: $1.15; Down -20%

International Stem Cell (ISCO.OB) = CurrentPrice: $0.45; Up 55%

LifeStem International (LSTM.OB) = Current Price: $0.0150; Up 285%

MultiCell Technologies (MCET.OB) = Current Price: $0.0160; Up 272%

Therapeutics (PSTI) = Current Price: $1.06; Up 67%

Stem Cell Therapy Intl (SCII.OB) = Current Price: $0.07; Up 40%

Stem Cell Innovations (SCLL.PK) = Current Price: $0.0095; Up 73%

Possible Catalyst for the Week:

- Again there is the potential for President Obama to give an executive order to allow funding for stem cell research; Bashers will say sell the news, but after last week's sell off, it wouldn't make a lot of sense. I'd expect at least a 2-day run if it happens.

- If it happens quickly, the DOW hitting 7000 pts could cause a huge upward move. There always seems to be a bear market rally once the market hits some technical or psychological points of support. With every sector basically at the mercy of the general market, I think they'll be a major opportunity to make money online with the huge bounce.

Trading/ Investing in "Penny" Stem Cell Stocks 101

2009-02-17T23:25:00.019-05:00

A lot of stock market traders and investors have recently entered into the Stem Cell sector because it is still undervalued and happens to be one of the few places right now where you can actually make money online. Because the vast majority of these stocks are $5.00/share or less with quite a few being less than $0.25/share, many people are venturing into the "penny stock" world for the first time. As a result, I decided to put together seven key concepts to remember when dealing specifically with Penny Stem Cell Stocks:

1. Penny Stem Cell Stocks Don't Trade Like Other Penny Stocks.

Let's not sugar coat it, most penny stocks are strictly pump and dumps. However, most of the penny stem cells stocks provide two things that typical penny stocks don't: legitimate reasoning for continued price appreciation and consistent volume.

2. These Stocks Are Volatile, But the Volatility Is Somewhat Controlled.

Most of the volatility in penny stem cell stocks is a function of extremely low prices and overall market uncertainty. Although the daily swings can be wild, a weekly or monthly chart quickly reveals a trading pattern that more so rivals stocks at $5 or $10 per share. As long as the outlook is not too short or long, these stocks have proven to be just as stable as any other stock in a market like this.

3. Curb Your Enthusiasm.

People kill me with stocks hovering around a penny or less with price targets of $1.00/share. I guess anything is possible, but that simply isn't very realistic. Pick reasonable price targets.

4. Curb Your Disgust.

A stock doesn't need to be axed because of one or two bad trading days. It's a penny stock so, as I stated earlier, expect volatility. If a stock can achieve 20% daily gains, don't be surprised to see 20% the other way at times. As long as there continues to be catalyst for upward movement, don't let a couple of downward swings discourage you.

5. Understand Standard Penny Stock Price Points.

$0.01, $0.025, $0.05, $0.10, and $0.25
These numbers represent psychological points of resistance. Stocks that develop a base at less than a penny tend to eventually hit a penny once it begins to run. Stocks that form a base at $0.01 often hit $0.025 (and so on and so forth). Just keep this in mind when determining entrance and exit points.

6. 100,000 Share Block Transactions - Institutional Buying?

100,000 share blocks does not necessarily represent the presence of institutional buying or selling. A $500 to $1000 transaction (which is what this represents) is as about as retail as they come. In other words don't get caught up in multi-million share volume. It's really not that much money relatively speaking.

7. Understand the Truth about Forums/Message Boards.

For the most part, message boards should be seen as nothing more than entertainment and marketing platforms. Often times the comments here are wild and completely off base. Also, reading them everyday can really be a drag. It's not that difficult to distinguish the bashers and pumpers, yet many still fall prey to their ridiculous manipulations of the truth. However, a board can occasionally be a decent place to get ideas and sometimes a "nugget" is dropped. In the likelihood that this should happen, you should always follow up with your own due diligence to check for accuracy (something that should constantly be done anyway if you own a stock). It also helps to understand what you get from different message boards. Here's my take on some of the more popular ones:

- Yahoo Finance: Basher heavy particularly on a down day; Pumper heavy on good days
- Google Finance: Quite a few bashers and pumpers, but not as bad as Yahoo
- Investor Village: Pretty good blend of bashers, pumpers, and sound advice
- Ihub: Mostly pumpers

--------------------------------------------------

Stem Cell Stocks 2/17/09 - 2/18/09

Thanks to a lots of media coverage from the Stem Cell Summit to begin the week on Tuesday, 2/17/09, Stem Cell Stocks got off to a blazing start. However, most of the gains were lost the following day due to news of a child fatality cause by the experimental treatment of neural stem cells. There was a swing of double digit gains on Tuesday to double digit losses on Wednesday. So, the week thus far has basically been a wash. Some will say that this has been a wild week. I'd say it's par for the course. Stocks of note are as follows:

Cord Blood America Inc.(CBAI.OB) = Current Price: $0.0104; Down -26% to begin the week. After showing lots of strength last week by remaining flat, the dumping has been pretty heavy due to false rumors of share dilution. $0.01/share has shown to have very strong support. CBAI.OB may not make up the deficit in the next two trading days, but I'd expect a strong finish to end the week.

Geron Corp (GERN) = Current Price = $5.74; Down -10% to begin the week. It still seems to be on its downward slide, but I really feel it stops here. On the bright side from a technical standpoint, the stock has almost completely "closed the gap" from its price prior to 1/23/09. This usually means the shorts will cover their positions and the slow steady rise that started in November should resume.

Stem Cell Company Stocks 2/15/09: The Week That Was

2009-02-15T17:01:00.011-05:00

Click Here for Spotlight on Cord Blood Banking Companies

Last week was a tough one for the Stem Cell stocks. Practically every stock that we follow was down this week. Astonishingly, for first time since our reference point of 1/23/09, a few stocks actually finished below the stock price of that day (most notably STEM).

Top Stem Cell Stock performer of the Week:

Cryo-Cell Intl (CCEL) = Up 18% on very low volume. It's possibly riding the coattails of the CBAI.OB's success, which impressively finished flat for the week

Worst Stem Cell Stock Performer of the Week:

Geron Corp (GERN) = Down -21%; It had been flying high pretty consistently until they announced a secondary offering, which gave people a reason to sell the stock off. I'd expect a pretty sharp recovery this week.

Stem Cell Stocks Performance Since 1/23/09

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Current Price: $2.54; Up 76%
Aastrom Biosciences (ASTM) = Current Price: $0.52; Unchanged
BioTime, Inc. (BTIM) = Current Price: $2.08; Unchanged
Celgene Corp (CELG) = Current Price: $52.31; Up 6%
Geron Corp (GERN) = Current Price: $6.38; Up 22%
ThermoGenesis (KOOL) = Current Price: $0.74; Up 36%
Osiris Therapeutics (OSIR) = Current Price: $20.11; Up 7%
StemCell Inc. (STEM) = Current Price: $2.12; Down -1%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.PK) = Current Price: $0.17; Up 42%
Athersys Inc. (ATHX) = Current Price: $0.97; Up 43%
Brainstorm Cell Therapeutics (BCLI.OB) = Current Price: $0.09; Down -10%
Bioheart Inc. (BHRT) = Current Price: Current Price: $1.00; Up 27%
Cord Blood America Inc. (CBAI.OB) = Current Price: $0.0141; Up 271%
Cyro-Cell Intl (CCEL.OB) = Current Price: $0.65; Up 41%
Neuralstem (CUR) = Current Price: $1.30; Down -9%
International Stem Cell (ISCO.OB) = CurrentPrice: $0.39; Up 34%
LifeStem International (LSTM.OB) = Current Price: $0.0140; Up 259%
MultiCell Technologies (MCET.OB) = Current Price: $0.0180; Up 319%
Pluristem Therapeutics (PSTI) = Current Price: $1.16; Up 82%
Stem Cell Therapy Intl (SCII.OB) = Current Price: $0.08; Up 60%
Stem Cell Innovations (SCLL.PK) = Current Price: $0.010; Up 82%

Possible Catayst for the Week

- 4th Annual Stem Cell Summit on February 17, 2009; several companies that we follow will be participating in this event; could provide more press for the sector by news outlets; see http://www.stemcellsummit.com/ for details

- Potential for President Obama to give an executive order to allow funding for stem cell research; It could be done this week to coincide with the freshly approved stimulus package

Final Thoughts

From the surface the charts of most stem cell stocks are beginning to breakdown and the bashers will be quick to point out GERN secondary offering coupled with PSTI's a couple of weeks ago is a dooming pattern of stock killing dilution. I say don't be fooled. Dilution is only a big deal when you are dealing with stocks with actual earnings. The fact of the matter is that besides the big market caps, most Biotech stocks rarely if ever have postive earnings. There value is typically measured by pipelines, patents, FDA approvals, and positive test studies. With all this said, I think this upcoming week is a very important one for the sector. After a couple weeks in a row now of sideways to downward trading action, it is important that stem cell stocks reestablish there strength. After such a sharp sell off, I expect GERN to lead the charge. This has the potential to be a good week to make money trading stem cell companies.

Publicly Traded Cord Blood Banking Companies

2009-02-12T23:09:00.008-05:00

As promised, here's a special spotlight on publicly traded cord blood banking companies. The business consists of storing the umbilical cords of new born babies. There are quite a few companies that offer these services in the United States, but only about 30 have met the strict FDA requirements to be considered private or family cord blood banks. Only four are publicly traded companies. Most traders/investors are familiar with names like Cord Blood America Inc. (CBAI.OB) and the slightly lesser known Cyro-Cell Intl (CCEL). However, a lot of people are surprised to find the third and fourth companies happen to be biophrama behemoth Celegene Corp. (CELG) and diagnostic instrument maker Perkin Elmer (PKI).

Cord Blood America Inc. (CBAI) has been one of the hottest Stem Cell stocks on the market. It is a holding company that owns subsidiary bank Cord Partners and CorCell
- Share price = $0.014 (as of 2/13/09)
- Received $4 million in funding in July 2008
- $3.3 million in revenues and $1.8 million in gross profits first 9 months of 2008
- Has established infrastructure so low burn rate
- Approximately 310 million shares outstanding; EPS (0.02)
- Approx. 10,000 customers in cord blood business

Cyro-Cell Intl (CCEL) is one of the oldest and largest private cord blood banks. It's been publicly traded since 1991, but shares are very thinly traded.
- Share price = $0.65 (as of 2/13/09)
- Partnership with National Institutes of Health (NIH) Clinical Center for study on Endometrial Stem Cells (working with NIH means a good chance at getting money from Obama's stimulus package)
- $13.1 million in revenue and $8.4 million in gross profits for the first 9 month of 2008;
- 11.7 million shares outstanding; EPS (.06)
- Approx. 175,000 customers in cord blood business

Celgene Corp (CELG) is the parent company of LifeBankUSA, the subsidary that runs the cord blood bank unit. They are the only company that offers the option of banking placental stem cells for family use.
- Share price = $52.31 (as of 2/13/09)
- LifeBankUSA was bought for approx. $60 million
- Approx. 20,000 customers in cord blood business

Perkin Elmer (PKI) is the parent company of Viacord, a cord blood banking business. Viacord was bought in 2007
- Share price = $14.46 (as of 2/13/09)
- Approx. 110,000 customers in cord blood business
- $60-$65 million in revenue form cord blood business
- Viacord was bought for $300 million

Although I did not include Neostem (NBS) in list of companies, it is often lumped into the group of cord blood banking companies. The difference is that Neostem specializes in storing adult stem cells. This is a completely different field with its own set of challenges.

Stem Cell Company Stocks 2/10/09: When to Exit Your Position

2009-02-07T23:24:00.011-05:00

All the Stem Cell Stocks are struggling to begin the week with the exception of only one.

Top Stem Cell Stock Performer 2/9/09 - 2/10/09:

Cord Blood America Inc. (CBAI) - Up 23% so far this week (was the only stem cell stock we track in the green at almost 7% on 2/10/09)

***Be on the lookout later this week for a post spotlighting the publicly traded Cord Blood Stem Cell Companies***

Topic of the Day: "I really believe that stem cell stocks have a lot of potential, but I don't want to make the mistake of holding on to them too long. When will be a good time to exit my position?"

Not even the red hot Stem Cell stocks were immune from today's rough stock market. It's easy to get lulled into thinking that a stock in a hot sector will continue to rise day after day, but it's days like today that bring stock traders or investors back down to reality. Based on history, stocks in bull market sectors can run for months. However, as the profits mount, it is nearly impossible to not think more and more about protecting gains. The 64 million dollar question becomes, "When should I exit my position?"

From a fundamental and technical viewpoint, there appears to be an awful lot of similarities between the Solar sector boom of 2007 and this current Stem Cell push. Both began in the mist of unprecedented economic circumstances (oil's rise and the credit crisis respectively). Both focus on much hyped technology that was previously underfunded. Finally, both obtained renewed government interest to catapult themselves forward. We can learn a lot from the recent booms in Solar, Coal, and other commodities. However, Solar appears to be the perfect comparison because its run happened to end before the recession began. I believe Solar will be a reliable indicator of what will happen with Stem Cells. Let's investigate the technical aspect a little closer. Check out the chart below:

This happens to be a 2 year chart of Canadian Solar (CSIQ). I chose this solar stock because it isn't an industry leader and its market cap was "middle of the road" compare to the other names in the sector. Notice the explosive first move of this stock in September 2007. There was over a 300% gain during the course of 4 months. What was interesting is that if you look at most of the other solar names, there first explosive move lasted between 3 and 7 months. The smaller market caps tended to run closer to 3 months and the larger caps ran closer to 7.

So, what does this all mean? If form holds true, names like Geron Corp (GERN) and StemCells (STEM) will have a continuous climb for 5 to 6 months before a multi-month pull back occurs. Although we have been spotlighting 1/23/09 as the key turning point with most stem cell stocks, GERN and STEM actually began to move a couple of weeks after the Presidential election. As a result, I would begin to get out of these names by April 2009. Practically all of the penny stock names in the sector began their run on 1/23/09. I wouldn't stay in them any more than 2 or 3 months tops.

In summary, the move in Stem Cell stocks, so far, have paralleled the solar names. If history is any indication, you may want to exit the relatively larger cap names after a run of 5 to 6 months and the smaller cap names like CBAI.OB and MCET.OB in 2 to 3 months. To a certain extent, you are taking a calculated risk by holding these names long term in the first place, but you're really gambling if you decide to hold beyond the time frames suggested. Basically, the figurative "bubble" could burst for most stem names by April or May of 2009, but you can sure make money online until then.

Stem Cell Company Stocks 2/7/09: The Week That Was

2009-02-07T15:09:00.015-05:00

Right now, trading Stem Cells stocks is the number one place to make money in the stock market. It has been a little over two weeks now since Geron Corp's ground breaking announcement on 1/23/09. In classic bull market fashion, the share price of every publicly traded Stem Cell company that we have followed since then remains significantly higher. After such explosive share price movement prior to last week, a substantial pullback would have been expected. However, the fact that most of the gains held is a testament to the strength of this sector. See below for our company list. Please note that Vitro Diagnostics (VODG.OB) was remove from due to a lack of volume. It has been replaced with BioTime, Inc. (BTIM). BioTime is interesting because of one of its subsidiaries called Embryome Sciences, Inc. It happens to be one of the lesser known stocks that deal directly with embryonic stem cells.

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA) = Current Price: $2.86; Up 99%
Aastrom Biosciences (ASTM) = Current Price: $0.64; Up 24%
BioTime, Inc. (BTIM) = Current Price: $2.45; Up 17%
Celgene Corp (CELG) = Current Price: $55.35; Up 13%
Geron Corp (GERN) = Current Price: $8.05; Up 55%
ThermoGenesis (KOOL) = Current Price: $0.77; Up 42%
Osiris Therapeutics (OSIR) = Current Price: $20.71; Up 10%
StemCell Inc. (STEM) = Current Price: $2.52; Up 17%

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.PK) = Current Price: $0.19; Up 58%
Athersys Inc. (ATHX) = Current Price: $1.10; Up 62%
Brainstorm Cell Therapeutics (BCLI.OB) = Current Price: $0.13; Up 25%
Bioheart Inc. (BHRT) = Current Price: Current Price: $0.99; Up 25%
Cord Blood America Inc. (CBAI.OB) = Current Price: $0.0146; Up 284%
Cryo-Cell Intl (CCEL.OB) = Current Price: $0.56; Up 22%
Neuralstem (CUR) = Current Price: $1.55; Up 8%
International Stem Cell (ISCO.OB) = CurrentPrice: $0.42; Up 45%
LifeStem International (LSTM) = Current Price: $0.130; Up 233%
MultiCell Technologies (MCET.OB) = Current Price: $0.022; Up 412%
Pluristem Therapeutics (PSTI) = Current Price: $1.35; Up 112%
Stem Cell Therapy Intl (SCII) = Current Price: $0.10; Up 100%
Stem Cell Innovations (SCLL.PK) = Current Price: $0.015; Up 109%

Notable Moves the Week of 2/2/09 - 2/6/09

Last Week's Top Performer: ARIA
- Up every day last week for a 71% total gain; Speculation is that it is an "Earnings Call" run up. Earnings are scheduled to be released on 2/12/09

Last Week's Worst Performer: PSTI
- Down 4 out of 5 days for a 25% total loss; Pulled back after company sold additional shares

Cord Blood America (CBAI.OB), which provides cord blood stem cell banking services and MultiCell Technologies (MCET.OB) were notable mostly in that they remained fairly flat for the week. Despite many critics declaring these two stocks as being nothing more than "pump and dumps", they appear to be holding up pretty well.

Possible Catalyst for Next Week

- Further progress in Congress regarding new stem cell legislation
- Senate passes the Stimulus Package
- Bio CEO & Investor Conference begins Monday February 9, 2009; Several of the companies that we are following have their CEO's presenting; See link for the entire list BIO CEO & Investor Conference

Don't forget to check back frequently to http://tradingstemcells2009.blogspot.com for all your Stem Cell stock "homework". I think the upcoming article on determining when to exit a position in a hot sector will be eye opening. So, check back soon!

Stem Cell Company Stocks 2/5/09: Why are the "Stems" Up today?

2009-02-05T22:31:00.015-05:00

Many of the Stem Cell Stocks moved up quite nicely today. This includes some previous “big movers” that finally bounced back after selling off for most of the week. You would have been making money today had you bought during the pullback. See below for some of the more notable moves:

Ariad Pharmaceuticals (ARIA) = Current Price: $2.68; Up 13%
- Up 4 straight days and 60% for week so far; It’s due for a pull back

Athersys, Inc.(ATHX) = Current Price: $1.10; Down 7%
- Pulling back a bit after a nice 4 day run

Cord Blood America Inc.(CBAI.OB) = Current Price: $0.0136; Up 12%
- Another stock coming back

MultiCell Technologies (MCET.OB) = Current Price: $0.023; Up 44%
- Coming off 5 straight down days, it may be preparing for another run

Pluristem Therapeutics (PSTI) = Current Price: $1.56; Up 20%
- Dropped from $2.21 to $1.14 in just a couple of days; seems to be coming back

Why Did Many of the Stem Cell Stocks Comeback Today?

The obvious answer would be that the market was up, so, the “stems” were up. Although there may be some validity to that thought, this sector has been in bull mode despite the DOW beginning to consistently dip below 8000. Consequently, it has got to be something else.

There is a very strong possibility that today’s strength was a function of Wall Street discovering “political action” involving the amendment of the Public Health Service Act. Yesterday and today, legislation was introduced and referred to the House Energy and Commerce Committee to provide for human embryonic stem cell research. The critics would say that this isn’t that big of a deal because there are still several stages remaining before any formal changes can occur. However, I am of the opinion that this is “stock moving” news because it further reinforces the rumor that government will make stem cell research a priority and sufficiently fund it. Don’t forget that the anticipation of “what could be” is far more powerful than “what is” when it comes to the stock market. Look for this positive momentum to continue Friday.

Hot Stem Cell Stock Topic to be Featured Next Week:
“I really believe in the potential of stem cell research and would rather invest than trade. How will I know when to exit my position?"

Check back to http://tradingstemcells2009.blogspot.com/ frequently where the stem cell stock “homework” is done for you.

Stem Cell Company Stocks 2/3/09: What has Last Week Taught Us

2009-02-03T22:05:00.009-05:00

Welcome back to http://tradingstemcells2009.blogspot.com . Let's take a look and see what has happened so far this week.

Notable Stem Cells Stocks moving up 2/2/09 - 2/3/09:
ARIA - UP 29%
ATHX - Up 21%
BHRT - UP 44% (Caution! Volume is still a little low on this one, but it appears to be increasing)

Notable Stem Cell Stocks pulling back 2/2/09 - 2/3/09:
KOOL - Down 14%

PSTI - Down 20%

What Have We Learned from the Stem Cell Stock Moves of Last Week?

When trading quick moving stocks like these, you have to have a game plan. Let look back at the past week and a half. Yes, a lot of the stem cell stocks began to move shortly after Barack Obama was elected president back in early November. However, I keep going back to Geron Corp’s announcement the morning of 1/23/09 because that was a defining turning point. Every stem cell stock we are following is up since that announcement. The first significant thing this brief stock history tells us is which stocks will give us volume. Volume is particularly needed when dealing with really small market caps stocks that frankly most of us had never really heard of prior to Geron’s press release.

Which Stem Cell Stocks Experienced Significant Moves First?

GERN and STEM. GERN, of course, moved because the big news came directly from them. STEM moved immediately because it has the most recognizable and notable name in the sector. However, the largest immediate mover was MCET.OB moving from $0.0043/share to as high as $0.07/share in 2 days. That’s over 1500%! From what I can see, there really isn’t anything that stands out about the company, but it moved quickly because it had the combination of having a super cheap share price and a relatively low number of outstanding shares (76 million per Google Finance)

Which Stem Cell Stocks Experienced Significant Moves Next?

CBAI.OB, SCLL.PK, and ACTC.PK. The first two listed stocks were comparable in share price to MCET.OB, but had a lot more shares outstanding (+300 Million and 1.1 Billion respectively). CBAI.OB has a strong PR machine, a solid business plan, and a notable investor. SCLL.PK has several stem cell related patents and is a potential takeover candidate. It appears that traders/ investors began to analyze companies in the sector a little more stringently and then "doubled down" on the ones that appeared to be the most solid. ACTC.PK, also fits this criteria despite being a little more expensive from a share price standpoint.

LSTM.OB also move pretty significantly around this time because its share price was comparable to MCET.OB, CBAI.OB and SCLL.PK. However, there are some questions regarding whether LSTM.OB is a serious stem cell company due to its involvement in other nonrelated fields.

During the later part of last week, the final big mover was PSTI. Its tiny 6 million share float made it too irresistible for traders late in game not to push up.

Based on the early stock trends of this week, it appears most of the stocks are either pulling back or leveling off. Wednesday or Thursday of this week may be a good time to begin thinking about establishing or re-establishing positions in your favorite stocks for the next run.

Final Synopsis

The stems cell stocks that have moved the most have had volume and at least one of the following criteria: super cheap share prices, low outstanding shares, and company legitimacy. After compiling all of this data it appears that if you want to be making money as quickly as possible, you want to watch CBAI.OB, SCLL.OB, ACTC.PK, PSTI, and MCET.OB. If you see one of these making a move, you’d better act fast.

Stem Cell Company Stocks 2/1/09

2009-02-01T20:30:00.017-05:00

Stem cell stocks are on fire right now! Let's take a look at how well these stocks have performed since the pivotal announcement by Geron Corp regarding the first human stem cell trial the morning of 1/23/09:

Market Cap over 50 Mil

Ariad Pharmaceuticals (ARIA) = Current Price: $1.67; Up 16%
Aastrom Biosciences (ASTM) = Current Price: $0.73: Up 43%
Celgene Corp (CELG) = Current Price: $52.95; Up 8%
Geron Corp. (GERN) = Current Price: $7.84; Up 50%
ThermoGenesis (KOOL) = Current Price: $0.77; Up 42%
StemCell, Inc. (STEM) = Current Price: $2.68; Up 25%

Market Cap Under 50 Mil

Advanced Cell Technology (ACTC.PK) = Current Price: $0.24; Up 100%
Athersys, Inc.(ATHX) = Current Price: $1.01; Up 49%
Brainstorm Cell Therapeutics Inc.(BCLI.OB) = Current Price: $0.16; Up 60%
Bioheart Inc.(BHRT) = Current Price: $0.80; Up 1%
Cord Blood America Inc.(CBAI.OB) = Current Price: $0.0151; Up 297%
Cyro-Cell International (CCEL.OB) = Current Price: $0.74; Up 61%
Neuralstem (CUR) = Current Price: $1.74; Up 22%
International Stem Cell Corp.(ISCO.OB) = Current Price: $0.51; Up 76%
LifeStem International (LSTM) = Current Price: $0.0199; Up 410%
MultiCell Technologies (MCET.OB) = Current Price: $0.024; Up 458%
Osiris Therapeutics (OSIR) = Current Price: $20.05; Up 6%
Pluristem Therapeutics (PSTI) = Current Price: $1.81; Up 184%
Stem Cell Therapy Intl (SCII) = Current Price: $0.11; Up 100%
Stem Cell Innovations (SCLL.PK) = Current Price: $0.016; Up 191%
Vitro Diagnostics (VODG.OB) = Current Price: $0.14; Up 133%

Possible Catalyst for Further Upward Price Movement This Week

The FDA is expected to rule whether they will approve a drug developed by GTC Biotherapeutics (Nasdaq: GTCB) called ATryn by 2/07/09. The drug is prepared from the milk of genetically engineered goats and is used as an anti-blood clotting medication. Because of the recommendation of an advisory panel, the FDA is expected to approve this drug for sale in the US. Although this development does not directly relate to stem cell research, it would further validate this new administration's commitment to using biotechnology and nontraditional methods for medical treatments. An approval by the FDA regarding the use of genetically engineered animals would be huge and reverberate throughout the Biotech community and, more importantly, Wall Street. Most of stocks in this sector will rise.

Notable Trends and Events for Key Stem Cell Stocks

- Pluristem Therapeutics (PSTI) - Stock has gone up 7 days in a row. What's appealing about this stock is that compared to all the other publicly traded stem cell companies, it has very few outstanding shares, steadily increasing volume and was one of the last stem cell stocks to make a big move. On Friday 1/29/09 they sold over a 1 million additional shares to raise money. After moving up so many days in a row, expect a pull back to come soon although it should be brief.

- Geron Corp (GERN) and StemCell (STEM) - Both stocks began to surge back in November 2008 and had huge pops after the news on 1/23/09. However, they each pulled back during the latter part of the week. Look for both stock to begin a slow steady incline to new highs starting this week.

- Advanced Cell Technology (ACTC.PK) - This stock actually began to really move at the start of 2009. Although it has gone up 100% since 1/23/09 it began the year at around $0.03/share and peaked at $0.29/ share. It looks to be finding a trading range at around $0.25/share, but I wouldn't be surprised to see it hit $1.00/ share in the next 3 months.

- Cord Blood America (CBAI.OB) - This cord blood stem cells stock went up 4 days in a row until finally pulling back Friday 1/29/09. Despite its "micro-penny" status, this stock appears to be one of the best candidates for quick price appreciation. Word has spread that Blue Cross Blue Shield recently purchased over 15 million shares. Although this doesn't represent that large of an investment monetarily, the fact that a large reputable entity has shown interest speaks volumes. I expect this stock will move from $0.015/share to $.05/share in the next two weeks.

My final word for traders or potential traders is to not fear the "Penny" status of stem cell stocks. The current stock price of these companies was simply a function of political suppression. Don't allow any negative thoughts you may have about trading stocks that are less than a dollar keep you from making money.

Making Money Trading Stem Cell Companies

2009-01-31T21:36:00.004-05:00

In 2008, most of the money made in the stock market was from the Energy sector. Solar, oil, and coal stocks all soared to record highs. However, nothing in life lasts forever and the energy bull market was no exception. Although I rarely agree with "Mad Money" host Jim Cramer, I do share his feeling that "there is always a bull market somewhere". In 2009, it appears the new bull market is in Biotechnology. More specifically, Stem Cell companies will lead the pack thanks to a philosophical change from government due to Barack Obama's new presidency.

Stem cell companies over the years have been over-hyped, yet under funded. Obama appears to be adamant in significantly increasing the funding in this area. The combination of new money entering the sector, along with renewed interest, and a bottoming market, makes for the perfect storm in stock trading.

The event that began to put teeth in the speculation of this Biotech surge was when the FDA approved Geron Corp's application for the world's first human clinical trial for embryonic stem cell-based therapy on 1/23/09. Since this epic announcement, the flood gates have opened on most publicly traded stem cell companies. It's barely been a week since the announcement and many of these companies have already seen incomprehensible appreciations in there stock price. I don't profess to be a wall street tycoon or Biotech expert. However, being an Mechanical Engineering graduate from Clemson University in 1998 and long time stock trader, I certainly understand patterns and technical reversals. Believe me when I say the rise has just only begun.

In this blog, I will chronicle the share price movement of many of these stem cell companies, identify catalyst for the week, and provide notable trends and events for specific stocks in the sector. In essence, this will be a daily one stop shop for you to see which stocks are ripe for trading. See below for the stocks I'll be following:

Market Cap Over 50 Million

Ariad Pharmaceuticals (ARIA)
Aastrom Biosciences (ASTM)
Celgene Corp (CELG)
Geron Corp. (GERN)
ThermoGenesis (KOOL)
StemCell, Inc. (STEM)

Market Cap Under 50 Million

Advanced Cell Technology (ACTC.PK)
Athersys, Inc.(ATHX)
Brainstorm Cell Therapeutics Inc.(BCLI.OB)
Bioheart Inc.(BHRT)
Cord Blood America Inc.(CBAI.OB)
Cyro-Cell International (CCEL.OB)
Neuralstem (CUR)
International Stem Cell Corp.(ISCO.OB)
LifeStem International (LSTM)
MultiCell Technologies (MCET.OB)
Osiris Therapeutics (OSIR)
Pluristem Therapeutics (PSTI)
Stem Cell Therapy Intl (SCII)
Stem Cell Innovations (SCLL.PK)
Vitro Diagnostics (VODG.OB)

Let's all make some money!